Document:

Exhibit 4.1
	 
	 
	 
	 
	 
	 
	 
	 
	WARRANT
	 
	to Purchase Common Stock of
	 
	Cadiz Inc.
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	Warrant No. A-1
	Original Issue Date:  November 29, 2016

 

    	 	1	 

     

    

 

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT
BE SOLD OR TRANSFERRED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SECURITIES IS EFFECTIVE UNDER THE SECURITIES ACT OR (II)
THE TRANSACTION IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS.

Original
Issue Date: November 29, 2016Warrant No. A-1

Warrant

to Purchase 306,530 Shares (Subject
to Adjustment) of Common Stock of

Cadiz Inc.

THIS IS TO CERTIFY THAT MSD CREDIT OPPORTUNITY
MASTER FUND, L.P. (“Investor”), or its registered assigns, is entitled,
at any time prior to the Expiration Date to purchase from Cadiz Inc., a Delaware corporation (the “Company”),
306,530 shares (subject to adjustment as provided herein) of the common stock, par value $0.01 per share, of the Company at a purchase
price of $0.01 per share (the initial “Exercise Price,” subject to
adjustment as provided herein).

This Warrant was issued in connection with
that certain Fifth Amendment to Amended and Restated Credit Agreement (the “Fifth Amendment”), dated as of November
29, 2016 (the “Fifth Amendment Effective Date”), by and among the Company, as a borrower, Cadiz Real Estate
LLC, as a borrower, Investor, as a lender, the other lenders party thereto, and Wells Fargo Bank, National Association, as agent
(the “Agent”), which amended that certain Amended and Restated Credit Agreement (as amended through and including
the Fifth Amendment Effective Date, and as subsequently amended from time to time, the “Credit Agreement”) attached
to that certain Amendment Agreement, dated as of October 30, 2013, by and among the Company, Cadiz Real Estate LLC, LC Capital
Master Fund, Ltd., the lenders party thereto, and the Agent, and is subject to the terms thereof.

		1.	DEFINITIONS

As used in this Warrant, the following
terms have the respective meanings set forth below, and to the extent such terms have the respective meaning set forth in the Credit
Agreement, such terms shall have such meaning as set forth in the Credit Agreement, provided, however, that if such
Credit Agreement is expired, terminated or otherwise discharged, such terms shall have the meaning set forth in the Credit Agreement
immediately prior to such expiration, termination or discharge:

“10-Day
VWAP” shall have the meaning ascribed to such term in the Credit Agreement.

“Affiliate”
of, or a Person “Affiliated” with, a specified Person means any other
Person directly or indirectly controlling, controlled by, or under common control with, that Person. For the purposes of this definition,
“control” (including, with correlative meanings, the terms “controlling,” “controlled by” and
“under common control with”), as applied to any Person, means the possession, directly or indirectly, of the power
(i) to vote 5% or more of the securities having ordinary voting power for the election of directors of such Person, or (ii) to
direct or cause the direction of the management and policies of that Person, whether through the ownership of voting securities
or by contract or otherwise.

“Agent” shall have
the meaning set forth in the preamble to this Warrant.

“Aggregation Date”
shall have the meaning set forth in Section 5.2 hereof.

“Applicable
Rate” shall have the meaning ascribed to such term in the Credit Agreement.

“Appraisal
Procedure” means the following procedure to determine the fair market value, as to any security, for purposes
of the definition of “Fair Market Value” or the fair market value,
as to any other property (in either case, the “Valuation Amount”).
The Valuation Amount shall be determined in good faith jointly by the Company and the Holder; provided, however,
that if such parties are not able to agree on the Valuation Amount within a reasonable period of time (not to exceed twenty (20)
Business Days), the Valuation Amount shall be determined by the mutual agreement of two (2) independent appraisers, one appointed
by the Company and one appointed by the Holder, with each appointed within ten (10) days of the Appraisal Procedure having been
first invoked by the Holder. The Company and the Holder shall submit their respective valuations and other relevant data to the
appraisers, and the appraisers shall, within twenty (20) days of the later of the two appraisers’ appointment dates, mutually
agree to a determination of the Valuation Amount. If such appraisers cannot mutually agree on the Valuation Amount by such date,
a third independent appraiser shall be chosen within 10 days of such date by the mutual consent of the first two appraisers. Such
third appraiser shall make a determination of the Valuation Amount within twenty (20) days of its appointment. If three (3) appraisers
shall have been appointed and made determinations of the Valuation Amount, then the average of the three (3) Valuation Amounts
shall be final and binding on the Company and the Holder as the final Valuation Amount, provided, however, that if
the determination of one appraiser differs by an amount equal to more than twice that of the middle of the three appraisers’
Valuation Amounts (the “Outlier Appraiser”), then the determination of the Outlier Appraiser shall be excluded
from determining the final Valuation Amount and the remaining two appraisers’ determinations of the Valuation Amount shall
be averaged and such average shall be final and binding upon the Company and the Holder as the final Valuation Amount. The Company
shall pay all of the fees and expenses incurred in conducting the Appraisal Procedure.

 

    	 	2	 

     

    

 

“beneficial owner”
and “beneficially own” shall have the meaning set forth under Section 13(d) of the Exchange Act.

“Beneficial Ownership Limitation”
has the meaning set forth in Section 5.1 hereof.

“Business
Day” shall have the meaning ascribed to such term in the Credit Agreement.

“Closing Share and Warrant Issuance
Agreement” means that certain Closing Share and Warrant Issuance Agreement by and between the Company and the Investor,
dated November 29, 2016.

“Commission”
means the Securities and Exchange Commission or any other federal agency then administering the Securities Act and other federal
securities laws.

“Common
Stock” means the common stock, par value $0.01 per share, of the Company as constituted on the Original Issue
Date, and any capital stock into which such Common Stock may thereafter be changed, and shall also include (i) capital stock of
the Company of any other class (regardless of how denominated) issued to the holders of shares of any Common Stock upon any reclassification
thereof which is also not preferred as to dividends or liquidation over any other class of stock of the Company and which is not
subject to redemption and (ii) shares of common stock of any successor or acquiring corporation received by or distributed to the
holders of Common Stock of the Company in the circumstances contemplated by Section 4.6 hereof.

“Company”
shall have the meaning set forth in the preamble to this Warrant.

“Credit
Agreement” shall have the meaning set forth in the preamble to this Warrant.

“Delivery
Notice” shall have the meaning set forth in Section 5.1(c) hereof.

“Designated
Office” shall have the meaning set forth in Section 9 hereof.

“Dilution Adjustment”
shall have the meaning set forth in Section 10.1(a) hereof.

“Dilution
Price” shall mean, with respect to each share of Common Stock, $9.05, subject to adjustments described in Sections
4.4, 4.5 and 4.6 hereof.

“DOJ” shall have the
meaning set forth in Section 6.4 hereof.

“DTC” shall have the
meaning set forth in Section 2.1(b) hereof.

“DWAC” shall have
the meaning set forth in Section 2.1(b) hereof.

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated
thereunder, all as the same shall be in effect at the time.

“Exercise
Date” shall have the meaning set forth in Section 2.1(a) hereof.

“Exercise
Notice” shall have the meaning set forth in Section 2.1(a) hereof.

“Exercise
Price” means, in respect of a share of Warrant Stock at any date herein specified, the initial Exercise Price
set forth in the preamble of this Warrant, as adjusted from time to time pursuant to Article 4 hereof.

“Expiration
Date” means (i) the fifth anniversary of the Original Issue Date, to be extended to allow for delayed exercise
and delivery of any Warrant Stock in accordance with Section 5.1(c) hereof, or (ii) if, at the Initial Exercise Date and pursuant
to Section 2.1(a) hereof, the Warrant does not become exercisable because no principal or interest amounts are outstanding under
the Credit Agreement, the Initial Exercise Date.

“Expiration Warrant Stock”
shall have the meaning set forth in Section 5.1(c) hereof.

“Fair
Market Value” means (i) as to any Common Stock listed or quoted on a Trading Market, the 10-Day VWAP determined
in respect of such primary Trading Market and (ii) as to any Common Stock not listed or quoted on a Trading Market or any other
security, (A) the Ten Day Average of the average closing prices of such security’s sales on all domestic securities exchanges
on which such security may at the time be listed, or (B) if there have been no sales on any such exchange such that the foregoing
Ten Day Average cannot be calculated, the average of the highest bid and lowest asked prices on all such exchanges at the end of
the Business Day immediately prior to the date that Fair Market Value is determined as of, or (C) if on any day such security is
not listed any domestic securities exchange such that neither the foregoing Ten Day Average nor the foregoing bid-and-asked price
average can be calculated, the average of the highest bid and lowest asked prices at the end of the Business Day immediately prior
to the date that Fair Market Value is determined as of in the domestic over-the-counter market as reported by the National Association
of Securities Dealers Automated Quotation System or similar organization (and in each such case excluding any trades that are not
bona fide, arm’s length transactions). If neither the foregoing clause (i) nor clause (ii) is applicable, then (i) the “Fair
Market Value” of such security as of an applicable determination date shall be as determined in good faith by the Board of
Directors of the Company, provided, however, that if shares of such security have been sold in arms-length transactions
by the Company within the 90-day period prior to the determination of the Fair Market Value, the Fair Market Value determined pursuant
to this sentence shall not be less than the highest price paid for such shares during such period, and (ii) with respect to property
other than securities, the “Fair Market Value” of such other property on the applicable determination date shall be
as determined in good faith by the Board of Directors of the Company.

 

    	 	3	 

     

    

 

“Fifth
Amendment” shall have the meaning set forth in the preamble to this Warrant.

“Fifth Amendment
Effective Date” shall have the meaning set forth in the preamble to this Warrant.

“Fifth
Amendment Warrants” means the Warrant together with all other warrants issued pursuant to the Fifth Amendment.

“FTC” shall have the
meaning set forth in Section 6.4 hereof.

“Governmental
Authority” shall have the meaning set forth in the Credit Agreement.

“Holder”
means with respect to any Warrant or share of Warrant Stock, the Person in whose name the Warrant or Warrant Stock is registered
on the books of the Company maintained for such purpose.

“Holder Group” shall
have the meaning set forth in Section 5.1(d) hereof.

“HSR Act” shall have
the meaning set forth in Section 6.4 hereof.

“Initial
Exercise Date” shall have the meaning set forth in Section 2.1(a) hereof.

“Interest Share Issuance”
shall have the meaning set forth in the Credit Agreement.

“Investor”
shall have the meaning set forth in the preamble to this Warrant.

“Lien”
means (i) any lien, mortgage, pledge, assignment, security interest, charge or encumbrance of any kind (including any agreement
to give any of the foregoing, any conditional sale or other title retention agreement, and any lease in the nature thereof) and
any option, trust or other preferential arrangement having the practical effect of any of the foregoing, and (ii) in the case of
securities, any purchase option, call or similar right of a third party with respect to such securities.

“Maximum Percentage”
shall have the meaning set forth in Section 5.1 hereof.

“Original
Issue Date” means November 29, 2016, the date on which the Original Warrant was issued by the Company pursuant
to the Closing Share and Warrant Issuance Agreement and the Fifth Amendment.

“Original
Warrant” means the Warrant as originally issued by the Company pursuant to the Closing Share and Warrant Issuance
Agreement and the Fifth Amendment.

“Outlier Appraiser”
shall have the meaning set forth in Article 1 hereof.

“Outstanding”
means, subject to Section 5.1(d) hereof, when used with reference to Common Stock, at any date as of which the number of shares
thereof is to be determined, all issued and actually outstanding shares of Common Stock, except shares then owned or held by or
for the account of the Company or any Subsidiary, and shall include all shares issuable in respect of outstanding scrip or any
certificates representing fractional interests in shares of Common Stock.

“Person”
means and includes natural persons, corporations, limited partnerships, general partnerships, limited liability companies, limited
liability partnerships, joint stock companies, joint ventures, associations, companies, trusts, banks, trust companies, land trusts,
business trusts or other organizations, whether or not legal entities, and Governmental Authority.

“Reference Price”
shall have the meaning set forth in Section 4.1 hereof.

“Related Issuances”
shall have the meaning set forth in Section 5.2 hereof.

“Required Holders”
means holders of outstanding Fifth Amendment Warrants representing more than 50% of the Warrant Stock issuable upon exercise of
such outstanding Fifth Amendment Warrants.

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated
thereunder, all as the same shall be in effect at the time.

“Stockholder Approval”
means the approval by the stockholders of the Company for purposes of terminating the issuance cap in respect of shares of Common
Stock set forth in Section 5.2 hereof.

“Subsidiary”
means any corporation, association, trust, limited liability company, partnership, joint venture or other business association
or entity (i) at least 50% of the Outstanding voting securities of which are at the time owned or controlled, directly or indirectly,
by the Company; or (ii) with respect to which the Company possesses, directly or indirectly, the power to direct or cause the direction
of the affairs or management of such Person.

“Ten
Day Average” means, with respect to any prices and in connection with the calculation of Fair Market Value, the
average of such prices over the ten Business Days ending on the Business Day immediately prior to the day as of which “Fair
Market Value” is being determined.

“Trading Day” means
any day that the primary Trading Market on which the Common Stock is listed or quoted is open for trading.

“Trading Market” means
any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB
or OTCQX (or any successors to any of the foregoing).

    	 	4	 

     

    

 

“Transfer Agent” shall
have the meaning set forth in Section 2.1(b) hereof.

“Valuation Amount”
shall have the meaning set forth in Article 1 hereof.

“Warrant
Price” means an amount equal to (i) the number of shares of Warrant Stock being purchased upon exercise of this
Warrant pursuant to Section 2.1 hereof, multiplied by (ii) the Exercise Price.

“Warrant”
means the Original Warrant and all warrants issued upon transfer, division or combination of, or in substitution for, the Original
Warrant, or any other like warrant subsequently issued to the Holder. All such foregoing warrants shall at all times be identical
as to terms and conditions, except as to the number of shares of Warrant Stock for which they may be exercised and their date of
issuance.

“Warrant
Stock” means the shares of Common Stock issued, issuable or both (as the context may require) upon the exercise
of the Warrant.

		2.	EXERCISE OF WARRANT

2.1                
Manner of Exercise.

(a)               
If any principal or interest amounts are outstanding under the Credit Agreement on the date that is the one hundred and
eightieth (180th) day following the Fifth Amendment Effective Date (the foregoing 180th day, the “Initial
Exercise Date”), then from the Initial Exercise Date and at any time before 4:00 P.M., Eastern Standard Time,
on the Expiration Date, the Holder of this Warrant may from time to time exercise this Warrant, on any Business Day, for all or
any part of the number of shares of Warrant Stock (subject to adjustment as provided herein) purchasable hereunder. In order to
exercise this Warrant, in whole or in part, the Holder shall (i) deliver to the Company at its Designated Office a written notice
of the Holder’s election to exercise this Warrant (an “Exercise Notice”)
substantially in the form attached to this Warrant as Annex A, which Exercise Notice shall be irrevocable and specify the
number of shares of Warrant Stock to be purchased, together with this Warrant and (ii) pay to the Company the Warrant Price. The
date on which such delivery and payment shall have taken place being hereinafter referred to as the “Exercise
Date.” If at the Expiration Date, this Warrant remains exercisable for any Warrant Stock, the Holder shall be
deemed to have delivered an Exercise Notice for such remaining Warrant Stock as of the Expiration Date and payment for such Warrant
Stock shall be deemed to be made by the Holder pursuant to Section 2.1(c)(i) hereof, unless the Holder notifies the Company otherwise
prior to the Expiration Date in respect of such delivery and payment. For the avoidance of doubt, once this Warrant shall become
exercisable in accordance with this Section 2.1, any subsequent payment of all remaining principal and interest outstanding under
the Credit Agreement shall not affect the ability of the Holder to exercise this Warrant.

(b)              
Subject to Article 5 hereof, upon receipt by the Company of such Exercise Notice, surrender of this Warrant and payment
of the Warrant Price (in accordance with Section 2.1(c) hereof), the Company shall cause its Transfer Agent to deliver the applicable
shares of Warrant Stock, and the Company shall deliver or cause to be delivered cash in lieu of any fraction of a share, to the
Holder and register such issued shares of Warrant Stock on the books of the Company as instructed by the Holder in the Exercise
Notice. The issued shares of Warrant Stock will be delivered by crediting the account of the Holder’s prime broker (as specified
by the Holder to the Company) with the Depository Trust Company (“DTC”)
through its Deposit/Withdrawal At Custodian (“DWAC”) system, whereby
the Holder’s prime broker shall initiate a DWAC transaction no later than 4:00 p.m. Eastern Standard Time on the third Trading
Day following the Exercise Date using its DTC participant identification number, and released by Continental Stock Transfer &
Trust Company, the Company’s transfer agent (the “Transfer Agent”),
at the Company’s direction. The Holder shall direct the broker-dealer at which the account or accounts to be credited with
the issued shares of Warrant Stock are maintained, which broker/dealer shall be a DTC participant, to initiate a transaction through
the DWAC system, instructing the Transfer Agent to credit such account or accounts with such shares of Warrant Stock. Such DWAC
instruction shall indicate the settlement date for the deposit of such shares of Warrant Stock, which shall be the Exercise Date.
The Company shall direct the Transfer Agent to credit the Holder’s account or accounts with such shares of Warrant Stock
pursuant to the information contained in the DWAC instruction. This Warrant shall be deemed to have been exercised and such shares
of Warrant Stock shall be deemed to have been issued, and the Holder or any other Person so designated to be named therein shall
be deemed to have become a holder of record of such shares of Warrant Stock for all purposes, as of the Exercise Date.

(c)               
Subject to Article 5 hereof, payment of the Warrant Price shall be made at the option of the Holder by one or more of the
following methods: (i) by delivery of a certified or official bank check or by wire transfer of immediately available funds in
the amount of such Warrant Price payable to the order of the Company, (ii) by instructing the Company to withhold a number of shares
of Warrant Stock then issuable upon exercise of this Warrant with an aggregate Fair Market Value equal to such Warrant Price, (iii)
by surrendering to the Company shares of Common Stock previously acquired by the Holder with an aggregate Fair Market Value equal
to such Warrant Price, or (iv) any combination of the foregoing. In the event of any withholding of Warrant Stock or surrender
of Common Stock pursuant to clause (ii), (iii) or (iv) of this Section 2.1(c) where the number of shares whose Fair Market Value
is equal to the Warrant Price is not a whole number, the number of shares withheld by or surrendered to the Company shall be rounded
up to the nearest whole share and the Company shall make a cash payment to the Holder based on the incremental fraction of a share
being so withheld by or surrendered to the Company in an amount determined in accordance with Section 2.3 hereof. The Holder will
receive fully paid and nonassessable shares of Warrant Stock upon any exercise of this Warrant.

(d)              
If this Warrant shall have been exercised in part, the Company shall, at the time of delivery of the shares of Warrant
Stock being issued in accordance with Section 2.1(c) hereof, deliver to the Holder a new Warrant evidencing the rights of the
Holder to purchase the unpurchased shares of Warrant Stock called for by this Warrant. Such new Warrant shall in all other respects
be identical to this Warrant.

    	 	5	 

     

    

 (e)               
Subject to Section 2.1(d) hereof, the Warrant delivered for exercise, and properly exercised by the Holder, in accordance
with Sections 2.1(a)-(c) and Article 5 hereof shall be canceled by the Company.

2.2                
Payment of Taxes. All shares of Warrant Stock issuable upon the exercise of this Warrant pursuant to the terms hereof
shall be validly issued, fully paid and nonassessable, issued without violation of any preemptive or similar rights of any stockholder
of the Company and free and clear of all Liens. The Company shall pay all expenses in connection with, and all taxes and other
governmental charges that may be imposed with respect to, the issue or delivery thereof.

2.3                
Fractional Shares. The Company shall not be required to issue a fractional share of Warrant Stock upon exercise of
the Warrant. As to any fraction of a share that the Holder of the Warrant, the rights under which are exercised in the same transaction,
would otherwise be entitled to purchase upon such exercise, the Company shall pay to such Holder an amount in cash equal to such
fraction multiplied by the Fair Market Value of one share of Common Stock on the Exercise Date.

		3.	TRANSFER, DIVISION AND COMBINATION

3.1                
Transfer. Upon compliance with the provisions of this Section 3.1, each transfer of this Warrant and all rights hereunder,
in whole or in part, shall be registered on the books of the Company to be maintained for such purpose, upon surrender of this
Warrant at the Designated Office and compliance with the terms hereof, together with a written assignment of this Warrant in the
form of Annex B attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer
taxes described in Section 2.2 hereof in connection with the making of such transfer. Upon such compliance, surrender and delivery
and, if required, such payment, the Company shall execute and deliver a new Warrant in the name of the assignee or assignees and
in the denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned and this Warrant shall promptly be cancelled.

3.2                
Mutilation or Loss. Upon receipt by the Company from any Holder of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant and an indemnity reasonably satisfactory to it (it being understood that
the written indemnification agreement of or affidavit of loss of the Holder shall be a sufficient indemnity) and, in case of mutilation,
upon surrender and cancellation hereof, the Company will execute and deliver in lieu hereof a new Warrant of like tenor to such
Holder; provided, however, that, in the case of mutilation, no indemnity shall be required if this Warrant in identifiable
form is surrendered to the Company for cancellation.

3.3                
Division and Combination. Subject to compliance with the applicable provisions of this Warrant, this Warrant may
be divided or, following such division, combined with other Warrants upon presentation hereof at the Designated Office, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its
agent or attorney. Subject to compliance with the applicable provisions of this Warrant as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice.

3.4                
Expenses. The Company shall prepare, issue and deliver at its own expense any new Warrant or Warrants required to
be issued hereunder.

3.5                
Maintenance of Books. The Company agrees to maintain, at the Designated Office, books for the registration and transfer
of the Warrants.

3.6                
Registration of Warrant Stock. Notwithstanding any termination, amendment, modification or supplement of the Credit
Agreement subsequent to the date hereof or, following the Initial Exercise Date, any subsequent payment of all remaining principal
and interest outstanding under the Credit Agreement, Section 2.4(h) of the Credit Agreement is hereby incorporated by reference
herein as if fully set forth herein as of the date hereof and shall apply mutatis mutandis to this Warrant and the Warrant
Stock.

    	 	6	 

     

    

 

		4.	ANTIDILUTION PROVISIONS

The number of shares of Warrant Stock
for which this Warrant is exercisable and the Exercise Price shall be subject to adjustment from time to time as set forth in this
Article 4.

4.1                
Upon Issuance of Common Stock. If the Company shall, at any time or from time to time after the Original Issue Date,
issue any shares of Common Stock, options to purchase or rights to subscribe for Common Stock, securities by their terms convertible
into or exchangeable for Common Stock, or options to purchase or rights to subscribe for such convertible or exchangeable securities
without consideration or for consideration per share less than the greater of (x) the Dilution Price in effect immediately prior
to the issuance of such Common Stock or securities and (y) the Fair Market Value per share of the Common Stock immediately prior
to such issuance (the greater of (x) and (y), the “Reference Price”), then such Exercise Price shall forthwith
be lowered to a price equal to the price obtained by multiplying:

(i)                
the Exercise Price in effect immediately prior to the issuance of such Common Stock, options, rights or securities by

(ii)              
a fraction of which (x) the numerator shall be the sum of (i) the number of shares of Common Stock Outstanding immediately
prior to such issuance and (ii) the number of additional shares of Common Stock which the aggregate consideration for the number
of shares of Common Stock so offered would purchase at the Reference Price and (y) the denominator shall be the number of shares
of Common Stock Outstanding immediately after such issuance.

4.2                
Upon Acquisition of Common Stock. If the Company or any Subsidiary shall, at any time or from time to time after
the Original Issue Date, directly or indirectly, redeem, purchase or otherwise acquire any shares of Common Stock, options to purchase
or rights to subscribe for Common Stock, securities by their terms convertible into or exchangeable for Common Stock, or options
to purchase or rights to subscribe for such convertible or exchangeable securities, for a consideration per share (plus, in the
case of such options, rights, or securities, the additional consideration required to be paid to the Company upon exercise, conversion
or exchange) greater than the Fair Market Value per share of Common Stock immediately prior to the earlier of (x) the announcement
of such event or (y) such event, then the Exercise Price shall forthwith be lowered to a price equal to the price obtained by multiplying:

(i)                
the Exercise Price in effect immediately prior to such event by

(ii)              
a fraction:

		(A)	the numerator of which is (1) the product of (a) the number of shares of Common Stock Outstanding and (b) the Fair Market Value
per share of Common Stock, in each case immediately prior to such event, minus (2) the aggregate consideration paid by the Company
in such event (plus, in the case of such options, rights, or convertible or exchangeable securities, the aggregate additional consideration
required to be paid to the Company upon exercise, conversion or exchange), and

		(B)	the denominator of which is the product (1) the number of shares of Common Stock Outstanding immediately after such event and
(2) the Fair Market Value per share of Common Stock immediately prior to such event.

4.3                
Provisions Applicable to Adjustments. For the purposes of any adjustment of the Exercise Price pursuant to Section
4.1 or 4.2 hereof, the following provisions shall be applicable:

(i)                
In the case of the issuance of Common Stock, options to purchase or rights to subscribe for Common Stock, securities by
their terms convertible into or exchangeable for Common Stock, or options to purchase or rights to subscribe for such convertible
or exchangeable securities for a consideration in whole or in part other than cash, the consideration other than cash shall be
deemed to be the Fair Market Value of the non-cash consideration.

    	 	7	 

     

    

 

(ii)              
In the case of the issuance of options to purchase or rights to subscribe for Common Stock, securities by their terms convertible
into or exchangeable for Common Stock, or options to purchase or rights to subscribe for such convertible or exchangeable securities:

		(A)	the aggregate maximum number of shares of Common Stock that potentially may be deliverable upon exercise of such options to
purchase or rights to subscribe for Common Stock at any time during the term thereof shall be deemed to have been issued at the
time such options or rights were issued and for a consideration equal to the consideration (determined in the manner provided in
subparagraph (i) above), if any, received by the Company upon the issuance of such options or rights plus the minimum purchase
price provided in such options or rights for the Common Stock covered thereby;

		(B)	the aggregate maximum number of shares of Common Stock that potentially may be deliverable upon conversion of or in exchange
for any such convertible or exchangeable securities or upon the exercise of options to purchase or rights to subscribe for such
convertible or exchangeable securities and subsequent conversion or exchange thereof at any time during the term thereof shall
be deemed to have been issued at the time such securities, options, or rights were issued and for a consideration equal to the
consideration received by the Company for any such securities and related options or rights (excluding any cash received on account
of accrued interest or accrued dividends), plus the additional consideration, if any, to be received by the Company upon the conversion
or exchange of such securities or the exercise of any related options or rights (the consideration in each case to be determined
in the manner provided in paragraph (i) above);

		(C)	on any increase in the number of shares or decrease in the effective exercise or conversion price of Common Stock deliverable
upon exercise of any such options, rights or securities or conversions of or exchanges of such securities, including any change
resulting from the anti-dilution provisions thereof, the Exercise Price shall forthwith be readjusted to such Exercise Price as
would have been obtained had the adjustment made upon the issuance of such options, rights or securities not converted prior to
such change or options or rights related to such securities not converted prior to such change been made upon the basis of such
change; and

		(D)	no further adjustment of the Exercise Price adjusted upon the issuance of any such options, rights, convertible securities
or exchangeable securities shall be made as a result of the actual issuance of Common Stock on the exercise of any such rights
or options or any conversion or exchange of any such securities.

4.4                
Upon Stock Dividends, Subdivisions or Splits. If, at any time after the Original Issue Date, the number of shares
of Common Stock Outstanding is increased by a stock dividend payable in shares of Common Stock or by a subdivision or split-up
of shares of Common Stock, then, following the record date for the determination of holders of Common Stock entitled to receive
such stock dividend, or to be affected by such subdivision or split-up, the Exercise Price and the Dilution Price shall each be
appropriately decreased by multiplying each price by a fraction, the numerator of which is the number of shares of Common Stock
Outstanding immediately prior to such increase and the denominator of which is the number of shares of Common Stock Outstanding
immediately after such increase in Outstanding shares.

    	 	8	 

     

    

 

4.5                
Upon Combinations or Reverse Stock Splits. If, at any time after the Original Issue Date, the number of shares of
Common Stock Outstanding is decreased by a combination or reverse stock split of the Outstanding shares of Common Stock into a
smaller number of shares of Common Stock, then, following the record date to determine shares affected by such combination or reverse
stock split, the Exercise Price and the Dilution Price shall each be appropriately increased by multiplying each price by a fraction,
the numerator of which is the number of shares of Common Stock Outstanding immediately prior to such decrease and the denominator
of which is the number of shares of Common Stock Outstanding immediately after such decrease in Outstanding shares.

4.6                
Upon Reclassifications, Reorganizations, Consolidations, Mergers or Dispositions of Assets. In the event of any capital
reorganization of the Company, any reclassification of the capital stock of the Company (other than a change in par value or from
par value to no par value or from no par value to par value or as a result of a stock dividend or subdivision, stock-split, reverse
stock-split or combination of shares), any consolidation or merger of the Company with or into another Person (where the Company
is not the surviving Person or where there is a change in or distribution with respect to the Common Stock) or sale, transfer or
other disposition of all or substantially all of the Company’s property, assets or business to another Person, each Warrant
shall after such reorganization, reclassification, consolidation, merger or disposition of assets be exercisable for the kind and
number of shares of stock or other securities or property of the Company or of the successor Person (if other than the Company)
resulting from such reorganization, reclassification, consolidation, merger or disposition of assets, if any, to which the holder
of the number of shares of Common Stock deliverable (immediately prior to the time of such reorganization, reclassification, consolidation,
merger or disposition of assets) upon exercise of such Warrant would have been entitled upon such reorganization, reclassification,
consolidation, merger or disposition of assets (without taking into account any limitations or restrictions on the exercisability
of this Warrant); and, in such case, appropriate adjustment (in form and substance satisfactory to the Holder) shall be made with
respect to the Holder’s rights under this Warrant to insure that the provisions of Article 4 hereof shall thereafter be applicable,
as nearly as possible, to this Warrant in relation to any shares of stock, securities or assets thereafter acquirable upon exercise
of this Warrant (and, for the avoidance of doubt, such adjustments shall include any appropriate adjustment to the Dilution Price
to realize the intended economic protection to the Holder of Section 4.1 hereof, as appropriate). The Company shall not effect
any such reorganization, reclassification, consolidation, merger or disposition of assets unless, prior to the consummation thereof,
the successor Person (if other than the Company) resulting from such reorganization, reclassification, consolidation, merger or
disposition of assets, shall assume, by written instrument, the obligation to deliver to the Holders of the Warrant such shares
of stock, securities or assets, which, in accordance with the foregoing provisions of this Section 4.6, such Holders shall be entitled
to receive upon such conversion. The provisions of this Section 4.6 shall similarly apply to successive reorganizations, reclassifications,
consolidations, mergers or dispositions of assets.

4.7                
Other Anti-Dilution Provisions. If the Company has issued or issues any securities of the Company to a financial
institution, lender, other credit provider, leasing company or other lessor in connection with the provisions of any financing
or lending agreements, containing provisions (including, without limitation, any of the terms of pricing, exercise price, anti-dilution
and registration rights) which are more favorable than those set forth herein, the Company will make such provisions (or any more
favorable portion thereof) available to the Holder and will enter into amendments necessary to confer such rights on the Holder.

4.8                
Appraisal Procedure. In any case in which the provisions of this Article 4 shall necessitate that the Appraisal Procedure
be utilized for purposes of determining an adjustment to the Exercise Price, the Company may defer, until the completion of the
Appraisal Procedure and the determination of the adjustment, (i) issuing to the Holder of any Warrant exercised after the date
of the event that requires the adjustment and before completion of the Appraisal Procedure and the determination of the adjustment,
the shares of capital stock issuable upon such exercise by reason of the adjustment required by such event and issuing to such
Holder only the shares of capital stock issuable upon such exercise before giving effect to such adjustment and (ii) paying to
such Holder any amount in cash in lieu of a fractional share of capital stock pursuant to Section 2.3 above; provided, however,
that the Company shall deliver to such Holder an appropriate instrument or due bills evidencing such Holder’s right to receive
such additional shares or such cash.

4.9                
Adjustment of Number of Shares Purchasable. Upon any adjustment of the Exercise Price as provided in Section 4.1,
4.2, 4.4, 4.5 and 4.6, the Holders of the Warrants shall thereafter be entitled to purchase upon the exercise thereof, at the Exercise
Price resulting from such adjustment, the number of shares of Warrant Stock (calculated to the nearest 1/100th of a share) obtained
by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares of Warrant Stock issuable
on the exercise hereof immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from
such adjustment.

    	 	9	 

     

    

 

4.10            
Increase of Number of Shares Purchasable. After giving effect to all other provisions in this Article 4 other than
this Section 4.10, the number of shares of Warrant Stock purchasable upon exercise of this Warrant shall be increased when the
Exercise Price is adjusted to an amount below the then-existing par value of the Warrant Stock, including successive adjustments
to the Exercise Price to an amount further below the then-existing par value. The number of additional shares purchasable upon
exercise of this Warrant shall be equal to the number obtained by dividing:

(i)                
The product of (A) the number of shares purchasable upon exercise of the Warrant before application of this Section 4.10
and (B) the difference between the then-existing par value per share of Warrant Stock minus the adjusted Exercise Price, by

(ii)              
The difference between the Fair Market Value of the Common Stock on the Exercise Date minus the then-existing par value
per share of Warrant Stock.

Concurrently with the foregoing adjustment to the number
of additional shares purchasable upon exercise of this Warrant, the Exercise Price shall be adjusted to be the then-existing par
value of the Warrant Stock.

4.11            
Form of Warrants. Irrespective of any adjustments of the number of shares of Warrant Stock purchasable or of the
Exercise Price, the Warrant theretofore or thereafter issued may continue to express the same price and number and kind of shares
as are stated in the Warrant issued on the Original Issue Date.

4.12            
Changes in Securities. Notwithstanding any provision in this Article 4 to the contrary and without limitation to
any other provision contained in this Article 4, in the event any securities of the Company are amended, modified or otherwise
altered by operation of this Article 4’s terms or otherwise in any manner whatsoever (including through the anti-dilution
provisions thereof) that results in (i) the reduction of the effective exercise, conversion or exchange price of such securities
payable upon the exercise for, or conversion or exchange into, Common Stock or other securities exercisable for, or convertible
or exchangeable into, Common Stock and/or (ii) such securities becoming exercisable for, or convertible or exchange into (A) more
shares or dollar amount of such securities which are, in turn exercisable for, or convertible or exchangeable into, Common Stock,
or (B) more shares of Common Stock, then such amendment, modification or other alteration shall be treated for purposes of Article
4 as if the securities which have been amended, modified or altered have been terminated and new securities have been issued with
the amended or modified terms. The Company shall make all necessary adjustments (including successive adjustments if required)
to the Exercise Price in accordance with this Article 4, but in no event shall the Exercise Price be greater than it was immediately
prior to the application of this Section 4.12 to the amendment, modification or alteration in question.

4.13            
Maximum Exercise Price. Except as provided in Section 4.5 above, at no time shall the Exercise Price per share of
Warrant Stock exceed the amount set forth in the preamble of this Warrant.

4.14            
Exceptions. Notwithstanding anything to the contrary, Article 4 hereof shall not apply to (i) (A) the issuance and
exercise of options to purchase shares of Common Stock and (B) the issuance of shares of Common Stock, in each case of the foregoing
clause (A) and (B), as made to eligible recipients pursuant to any equity incentive plan duly adopted by the board of directors
of the Company in the ordinary course of business, or (ii) any issuance of shares of Common Stock upon conversion of the Company’s
convertible debt securities outstanding as of the Business Day immediately preceding the Original Issue Date.

4.15            
Notice of Adjustment of Exercise Price. Whenever the number of shares of Common Stock for which this Warrant is exercisable
or the Exercise Price is adjusted as provided under Article 4 hereof:

(i)                
the Company shall compute the adjusted Exercise Price in accordance with this Article 4 and shall prepare a certificate
signed by the treasurer or chief financial officer of the Company setting forth the adjusted Exercise Price and showing in reasonable
detail the facts upon which such adjustment is based, and such certificate shall forthwith be filed at the Designated Office; and

(ii)              
a notice stating that the Exercise Price has been adjusted and setting forth the adjusted Exercise Price shall forthwith
be prepared by the Company, and as soon as practicable after it is prepared, such notice shall be mailed by the Company at its
expense to the Holder at its last address as it shall appear in the warrant register. If the Board of Directors of the Company
makes any determination of Fair Market Value for purposes of determining such proposed adjustment, then, within thirty (30) days
of the Holder’s receipt of such notice, the Holder shall have the right to use the Appraisal Procedure to determine Fair
Market Value with respect to the entire proposed adjustment.

4.16            
Independent Application. Except as otherwise provided herein, all sections of this Article 4 are intended to operate
independently of one another (but without duplication). If an event occurs that requires the application of more than one section
of this Article 4, all applicable sections shall be given independent effect without duplication.

    	 	10	 

     

    

 

		5.	BENEFICIAL OWNERSHIP LIMITS; ISSUANCE CAP

5.1                
Beneficial Ownership Limitation.

(a)               
Notwithstanding anything to the contrary contained herein, the Holder shall not receive shares of Warrant Stock upon exercise
of the Warrant to the extent (but only to the extent) that such exercise or receipt would cause the Holder Group to become, directly
or indirectly, a beneficial owner of a number of shares of Common Stock that exceeds the Maximum Percentage of Common Stock Outstanding
as of the Exercise Date (the “Beneficial Ownership Limitation”). The
Beneficial Ownership Limitation (i) may be increased or decreased, in the Holder’s sole discretion, upon 61 days’ written
notice to the Company by the Holder, provided, however, that in no event shall the Holder increase such Beneficial
Ownership Limitation to raise the Maximum Percentage in excess of 19.99% as of any date of shares of Common Stock Outstanding from
the date hereof through the Expiration Date and (ii) shall automatically be increased to a Maximum Percentage of 19.99% on the
date that is 15 days prior to the Expiration Date.

(b)              
At the time of delivery of any Exercise Notice, the Holder shall notify the Company if, and only if, a Holder Group would
beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation upon giving effect to such
Exercise Notice. For the avoidance of doubt, upon any failure by the Holder to deliver such notice, any subsequent purported delivery
in such instance of Warrant Stock shall be void and have no effect pursuant to Section 5.1(c) hereof.

(c)               
Any purported delivery of Warrant Stock pursuant to Section 2.1(b) hereof, and any purported payment by the Holder of the
Warrant Price pursuant to Section 2.1(a) and 2.1(c) hereof, in connection with the exercise of the Warrant shall be void and have
no effect to the extent (but only to the extent) that such delivery would violate the Beneficial Ownership Limitation. If any delivery
of Warrant Stock owed to the Holder following exercise of the Warrant is not made, in whole or in part, as a result of the Beneficial
Ownership Limitation, the Company’s obligation to make such delivery shall not be extinguished and the Company shall deliver
such Warrant Stock as promptly as practicable after the Holder gives written notice to the Company that such delivery would not
violate the Beneficial Ownership Limitation (the “Delivery Notice”), provided, however, that (i)
the Holder shall be deemed to have exercised this Warrant in respect of any such delayed Warrant Stock (other than at the Expiration
Date) as of the date of the applicable Delivery Notice and (ii) for the avoidance of doubt, Article 4 hereof and Article 10 hereof
shall remain in full force and effect for such period of delay, and provided, further, however, that at the
Expiration Date and in accordance with the deemed Exercise Notice under Section 2.1(a) hereof, if, without giving effect to the
Beneficial Ownership Limitation, the Warrant would be exercisable for any Warrant Stock, (i) the Holder shall be entitled to receive
from the Company any such remaining Warrant Stock under the terms of this Warrant until such time as the Beneficial Ownership Limitation
would not prohibit such delivery (such Warrant Stock at the Expiration Date, the “Expiration Warrant Stock”),
(ii) the Holder shall be deemed to have exercised this Warrant in respect of all such Expiration Warrant Stock as of the date of
such Holder’s receipt from the Company of the Expiration Warrant Stock (which exercise shall be subject to Article 4 hereof
but not be subject to Sections 4.1 through 4.3 hereof) and (iii) for the avoidance of doubt, Article 10 hereof shall remain in
full force and effect for the period until the delivery of the Expiration Warrant Stock.

(d)              
For purposes of this Section 5.1, (i) the term “Maximum Percentage”
shall mean 4.99%; provided, however, that if at any time after the date hereof the Holder Group beneficially owns
in excess of 4.99% of the Outstanding Common Stock (excluding any Common Stock that could be acquired by exercise of this Warrant),
then the Maximum Percentage shall automatically increase to 9.99% so long as any Holder Group owns in excess of 4.99% of such
Common Stock (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon the time when no Holder Group beneficially
owns in excess of 4.99% of such Outstanding Common Stock); and (ii) the term “Holder
Group” shall mean any group in respect of Common Stock, where “group” has the meaning established
under Section 13(d) of the Exchange Act and the rules promulgated thereunder, if the Holder or any other Person having beneficial
ownership of Common Stock beneficially owned by the Holder is a member of such group. In determining the number of shares of Common
Stock Outstanding for purposes of this Section 5.1 and the number of shares that the Holder may at any time acquire pursuant to
the Beneficial Ownership Limitation and the other terms of this Section 5.1, the Holder shall give effect to the last sentence
of Rule 13d-3(d)(1)(i) as promulgated under the Exchange Act, and the Holder may rely on the number of outstanding shares of Common
Stock as reflected in (x) the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with
the Commission, as the case may be, (y) a more recent public announcement by the Company or (z) a more recent notice by the Company
or its transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon written or oral
request of the Holder, the Company shall, within two (2) Business Days of such request, confirm orally and in writing to the Holder
the number of shares of Common Stock then Outstanding. For the avoidance of doubt, if at any time after the Initial Exercise Date
and through the Expiration Date, any Holder Group would become the beneficial owner of any shares of Common Stock pursuant to
an Interest Share Issuance to such Holder Group, the effect of the Beneficial Ownership Limitation in respect of Warrant Stock
shall be determined after giving effect to the beneficial ownership of such shares of Common Stock pursuant to an Interest Share
Issuance pursuant to Section 2.4(f) of the Credit Agreement for purposes of effectuating such intended beneficial ownership limitation
under the Credit Agreement. The provisions of this Section 5.1 shall be construed, corrected and implemented in a manner so as
to effectuate the intended Beneficial Ownership Limitation.

    	 	11	 

     

    

5.2                
Issuance Cap. Unless Stockholder Approval has been previously obtained, in the event that any issuance of Warrant
Stock upon the exercise of this Warrant would, together with (i) any other issuance of shares of Common Stock by the Company to
any holder of any Fifth Amendment Warrant and/or (ii) any issuance of shares of Common Stock pursuant to an Interest Share Issuance
that would, in each case, be aggregated with such proposed issuance under this Warrant for determining whether such issuances collectively
would require approval by a vote of Company stockholders under the applicable listing rules of the Nasdaq Global Market, any successor
stock exchange operated by the NASDAQ Stock Market LLC or any successor thereto (such other issuances in the foregoing clauses
(i) and (ii), the “Related Issuances”), exceed 19.99% of the Common
Stock Outstanding on May 24, 2016 (the “Aggregation Date”), the Holder shall receive only a number of shares
of Common Stock, rounded down to the nearest whole number, equal to (A) the maximum number of shares of Common Stock which
could be issued to the Holder and any other recipients of any then-proposed Related Issuances in the aggregate without the Related
Issuances exceeding 19.99% of the Common Stock Outstanding on the Aggregation Date (such maximum number calculated by giving effect
to any then-proposed Related Issuances in connection with any Interest Share Issuance last) multiplied by a ratio equal to (B) (1)
the number of shares of Common Stock that would be otherwise received by the Holder under this Warrant divided by (2) the
number of all of the shares of Common Stock that would be otherwise received by the Holder under this Warrant and the recipients
of any then-proposed Related Issuances in the aggregate. To the extent the Holder is entitled to receive from the Company a number
of shares of Warrant Stock reduced by this Section 5.2, the Company shall pay to the Holder, in satisfaction of the Company’s
obligation to deliver such Warrant Stock, a cash amount equivalent to the Fair Market Value, determined as of the Exercise Date,
of the number of shares of Warrant Stock by which such exercise was reduced within three (3) Business Days of the Exercise Date.

		6.	NO IMPAIRMENT; REGULATORY COMPLIANCE AND COOPERATION

6.1                
No Impairment. The Company shall not by any action, including, without limitation, amending its charter documents
or through any reorganization, reclassification, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other similar voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate to protect the rights of the Holder against impairment. Without limiting the generality of the foregoing,
the Company shall take all such action as may be necessary or appropriate in order that the Company may validly and legally issue
fully paid and nonassessable shares of Warrant Stock upon the exercise of this Warrant, free and clear of all Liens, and shall
use its best efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof as may be necessary to enable the Company to perform its obligations under this Warrant. The Company shall not take any
action, enter into any transaction or suffer to exist any event, action or state of facts that would cause the Exercise Price to
be adjusted below the then existing par value of Common Stock (unless the Common Stock is changed to capital stock with no par
value); provided, however, that nothing herein will prevent the operation of any other provision of this Warrant,
including the anti-dilution provisions of Article 4 hereof.

6.2                
No Dilution. If any event shall occur as to which the provisions of Article 4 hereof are not strictly applicable
but the failure to make any adjustment would adversely affect the purchase rights represented by the Warrant in accordance with
the essential intent and principles of such Article (including, without limitation, the issuance of securities other than Common
Stock which have the right to participate in distributions to the holders of Common Stock, the granting of “phantom stock”
rights or “stock appreciation rights”), then, in each such case, the Company shall, upon the request of any Holder,
appoint an investment banking firm of recognized national standing, or any other financial expert that does not (or whose directors,
officers, employees, Affiliates or stockholders do not) have a direct or material indirect financial interest in the Company or
any of its Subsidiaries, who has not been, and, at the time it is called upon to give independent financial advice to the Company,
is not (and none of its directors, officers, employees, Affiliates or stockholders are) a promoter, director or officer of the
Company or any of its Subsidiaries, which shall give their opinion upon the adjustment, if any, on a basis consistent with the
essential intent and principles established in Article 4 hereof, necessary to preserve, without dilution, the purchase rights,
represented by this Warrant. Prior to such determination by such investment banking firm, the Company and the requesting Holder(s),
respectively, shall specify the amount, if any, of the adjustment that such party has determined in good faith to be appropriate.
The adjustment determined by the investment banking firm shall be within the range of the adjustments thus proposed by the parties,
and the costs and fees of such investment banking firm shall be allocated proportionately between the Company, on one hand, and
the Holder, on the other, based on the respective differences between the amount of the adjustment as determined by such investment
banking firm and the amounts of such adjustment proposed by the Company and the Holder. Upon receipt of such opinion, the Company
will promptly mail a copy thereof to the holders of the Warrants and shall make the adjustments described therein.

    	 	12	 

     

    

 

6.3                
Other Agreements. The Company is not a party to or bound in any manner under, and covenants that it will not enter
into at any time after the date hereof, any agreement or contract (whether written or oral) with respect to any of its securities
which prevents the Company from complying in any respect with the rights granted by the Company hereunder.

6.4                
Antitrust Notification. If the Holder determines, in its sole judgment upon the advice of counsel, that an exercise
of this Warrant pursuant to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended (the “HSR Act”), the Company shall file, within seven (7) Business Days after receiving
notice from the Holder of the applicability of the HSR Act and a request to so file, with the United States Federal Trade Commission
(the “FTC”) and the United States Department of Justice (the “DOJ”) the notification and
report form and any supplemental information required to be filed by it pursuant to the HSR Act in connection with the exercise
of this Warrant. Any such notification and report form and supplemental information will be in full compliance with the requirements
of the HSR Act. The Company will furnish to the Holder promptly (but in no event more than five (5) business days) such information
and assistance as such holder may reasonably request in connection with the preparation of any filing or submission required to
be filed by the Holder under the HSR Act. The Company shall respond promptly after receiving any inquiries or requests for additional
information from the FTC or the DOJ (and in no event more than three (3) business days after receipt of such inquiry or request).
The Company shall keep such holder apprised periodically and at such holder's request of the status of any communications with,
and any inquiries or requests for additional information from, the FTC or the DOJ. The Company shall bear all filing or other fees
required to be paid by the Company under the HSR Act or any other applicable law in connection with such filings and all costs
and expenses (including, without limitation, reasonable attorneys' fees and expenses) incurred by the Company in connection with
the preparation of such filings and responses to inquiries or requests. The Company shall also bear 50% of all filing or other
fees required to be paid by the Holder (or the “ultimate parent entity” of the Holder, if any) under the HSR Act or
any other applicable law in connection with such filings and 50% of all costs and expenses (including, without limitation, reasonable
attorneys' fees and expenses) incurred by the Holder in connection with the preparation of such filings and responses to inquiries
or requests, and the Holder shall bear the remaining 50% of such fees, costs and expenses. In the event that this Section 6.4 is
applicable to any exercise of this Warrant, the issuance to the Holder of the applicable Warrant Stock Shares, and the payment
by the Holder of the Warrant Price therefor, shall be subject to the expiration or earlier termination of the waiting period under
the HSR Act (with the Exercise Date being deemed to be the date immediately following the date of such expiration or early termination).

		7.	RESERVATION AND AUTHORIZATION OF COMMON STOCK

7.1                
Reservation. The Company shall at all times reserve and keep available for issuance upon the exercise of the Warrant
such number of its authorized but unissued shares of Common Stock as will be required for issuance of the Warrant Stock. All shares
of Warrant Stock issuable pursuant to the terms hereof, when issued upon exercise of this Warrant with payment therefor in accordance
with the terms hereof, shall be duly and validly issued and fully paid and nonassessable, not subject to preemptive rights and
shall be free and clear of all Liens. Before taking any action that would result in an adjustment in the number of shares of Warrant
Stock for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions
thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction over such action.
If any shares of Warrant Stock required to be reserved for issuance upon exercise of the Warrant require registration or qualification
with any Governmental Authority under any federal or state law (including the Securities Act and state securities laws) before
such shares may be so issued, the Company will use its commercially reasonable efforts to register and qualify such shares as soon
as practicable and at its expense.

7.2                
Corporate Action. Before taking any action that would cause an adjustment reducing the Exercise Price below the then-par
value (if any) of the shares of Warrant Stock deliverable upon exercise of the Warrant or that would cause the number of shares
of Warrant Stock issuable upon exercise of the Warrant to exceed (when taken together with all other Outstanding shares of Common
Stock) the number of shares of Common Stock that the Company is authorized to issue, the Company will take any corporate action
that, in the opinion of its counsel, is necessary in order that the Company may validly and legally issue the full number of fully
paid and nonassessable shares of Warrant Stock issuable upon exercise of the Warrant at such adjusted exercise price.

    	 	13	 

     

    

 

		8.	NOTICE OF CORPORATE ACTIONS; TAKING OF RECORD; TRANSFER BOOKS

8.1                
Notices of Corporate Actions.

In case:

(a)               
the Company shall grant to the holders of its Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class; or

(b)              
the Company shall declare to the holders of its Common Stock any dividend or distribution; or

(c)               
of any reclassification of the Common Stock (other than a subdivision or combination of the Outstanding shares of Common
Stock), or of any consolidation, merger or share exchange to which the Company is a party and for which approval of any stockholders
of the Company is required, or of the sale or transfer of all or substantially all of the assets of the Company; or

(d)              
of the voluntary or involuntary dissolution, liquidation or winding up of the Company;

(e)               
the Company or any Subsidiary shall commence a tender offer for all or a portion of the Outstanding shares of Common Stock
(or shall amend any such tender offer to change the maximum number of shares being sought or the amount or type of consideration
being offered therefor); or

(f)               
the Company or any Subsidiary takes any action or any event or circumstance occurs that impacts the rights of a Holder set
forth herein or in the Credit Agreement, as applicable;

then the Company shall cause to be filed at the Designated
Office, and shall cause to be mailed to the Holder at its last addresses as they shall appear in the warrant register, at least
30 days prior to the applicable record, effective or expiration date hereinafter specified, a notice stating (x) the date on which
a record is to be taken for the purpose of such dividend, distribution or granting of rights or warrants, or, if a record is not
to be taken, the date as of which the holders of Common Stock of record who will be entitled to such dividend, distribution, rights
or warrants are to be determined, (y) the date on which such reclassification, consolidation, merger, share exchange, sale, transfer,
dissolution, liquidation or winding up is expected to become effective, and the date as of which it is expected that holders of
Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, share exchange, sale, transfer, dissolution, liquidation or winding up, or (z)
the date on which such tender offer commenced, the date on which such tender offer is scheduled to expire unless extended, the
consideration offered and the other material terms thereof (or the material terms of the amendment thereto). Such notice shall
also set forth such facts with respect thereto as shall be reasonably necessary to indicate the effect of such action on the Exercise
Price and the number and kind or class of shares or other securities or property which shall be deliverable or purchasable upon
the occurrence of such action or deliverable upon exercise of the Warrants. Neither the failure to give any such notice nor any
defect therein shall affect the legality or validity of any action described in clauses (a) through (e) of this Section 8.1.

8.2                
Taking of Record. In the case of all dividends or other distributions by the Company to the holders of its Common
Stock with respect to which any provision hereof refers to the taking of a record of such holders, the Company will in each such
case take such a record and will take such record as of the close of business on a Business Day.

    	 	14	 

     

    

 

8.3                
Closing of Transfer Books. The Company shall not at any time close its stock transfer books or warrant transfer books
so as to result in preventing or delaying the exercise or transfer of any Warrant.

		9.	OFFICE OF THE COMPANY

9.1                
As long as the Warrant remains outstanding, the Company shall maintain an office or agency, which may be the principal executive
offices of the Company (the “Designated Office”), where the Warrant
may be presented for exercise, registration of transfer, division or combination as provided in this Warrant. Such Designated Office
shall initially be the office of the Company at 550 South Hope Street, Suite 2850, Los Angeles, California 90071. The Company may
from time to time change the Designated Office to another office of the Company or its agent within the United States by notice
given to any registered Holders at least ten (10) Business Days prior to the effective date of such change.

		10.	DILUTION ADJUSTMENT

10.1            
Dilution Adjustment.

(a)               
In the event that any dividends are declared or paid or any other distribution is made on or with respect to the Common
Stock, the Holder as of the record date established by the Board of Directors of the Company for such dividend or distribution
on the Common Stock shall be entitled to receive a fee (the “Dilution Adjustment”)
in an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends
or distribution that such Holder would have received had the Warrant been exercised as of the date immediately prior to the record
date for such dividend or distribution, such Dilution Adjustment to be payable on the same payment date established by the Board
of Directors of the Company for the payment of such dividend or distribution; provided, however, that if the Company
declares and pays a dividend or distribution on the Common Stock consisting in whole or in part of Common Stock, then no such Dilution
Adjustment shall be payable in respect of the Warrant on account of the portion of such dividend or distribution on the Common
Stock payable in Common Stock and in lieu thereof the applicable adjustment in Article 4 hereof shall apply. The record date for
any such Dilution Adjustment shall be the record date for the applicable dividend or distribution on the Common Stock, and any
such Dilution Adjustment shall be payable to the Persons in whose name the Warrant is registered at the close of business on the
applicable record date.

(b)              
No dividend shall be paid or declared on any share of Common Stock (other than dividends payable in Common Stock for which
an adjustment was made pursuant to Article 4 hereof), unless the Dilution Adjustment, payable in the same consideration and manner,
is simultaneously paid or provided for, as the case may be, in respect of this Warrant in an amount determined as set forth in
this Section 10.1. For purposes of this Warrant, the term “dividends” shall include any pro rata distribution by the
Company, out of funds of the Company legally available therefor, of cash, property, securities (including, but not limited to,
rights, warrants or options and/or securities in connection with a spin-off of the Company) or other property or assets to the
holders of the Common Stock, whether or not paid out of capital, surplus or earnings other than liquidation.

    	 	15	 

     

    

(c)               
Prior to declaring any dividend or making any distribution on or with respect to shares of Common Stock, the Company shall
take all prior corporate action necessary to authorize the issuance of any securities payable as the Dilution Adjustment in respect
of the Warrant.

		11.	MISCELLANEOUS

11.1            
No Implied Waivers. No failure or delay by any party in exercising any right, power or privilege hereunder shall
operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or
the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive
of any rights or remedies provided by law.

11.2            
Notices. All notices, requests, consents and other communications required or permitted hereunder shall be in writing
and shall be hand delivered or mailed postage prepaid by registered or certified mail or transmitted by facsimile transmission
(with immediate telephonic confirmation thereafter) or transmitted by email:

(a)               
If to the Holder:

MSD CREDIT OPPORTUNITY MASTER FUND, L.P.

645 Fifth Avenue

21st Floor

New York, NY 10022-5910

Attention: Marcello Liguori

Facsimile No.: (212) 303-1650

Telephone No.: (212) 303-1634

Email: mliguori@msdcapital.com

with a copy to (which shall not constitute
notice):

Skadden, Arps, Slate, Meagher & Flom LLP

4 Times Square

New York, NY 90071

Attention: Harvey Uris

Facsimile No.: (212) 735-2000

Telephone No.: (212) 735-3000

Email: harvey.uris@skadden.com, or

(b)              
If to the Company:

Cadiz Inc.

550 South Hope Street, Suite 2850

Los Angeles, California 90071

Attention: Chief Financial Officer

Facsimile No.: 213-271-1614

Email: tshaheen@cadizinc.com

with a copy to (which shall not constitute
notice):

Mitchell Silberberg & Knupp LLP

11377 W. Olympic Blvd.

Los Angeles, CA 90065

Facsimile No.: (310) 312-3100

Attention: Kevin Friedmann, Esq.

Email: kxf@msk.com

or at such other address as the
parties each may specify by written notice to the others, and each such notice, request, consent and other communication shall
for all purposes of the Warrant be treated as being effective or having been given when delivered if delivered personally, upon
receipt of facsimile confirmation if transmitted by facsimile, upon transmission of email if transmitted by email, or, if sent
by mail, at the earlier of its receipt or 72 hours after the same has been deposited in a regularly maintained receptacle for the
deposit of United States mail, addressed and postage prepaid as aforesaid.

    	 	16	 

     

    

 

11.3            
Indemnification. If the Company fails to make, when due, any payments provided for in this Warrant, the Company shall
pay to the Holder (a) interest at the Applicable Rate on any amounts due and owing to such Holder and (b) such further amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees and expenses
incurred by such Holder in collecting any amounts due hereunder. The Company shall indemnify, defend and hold harmless the Holder
and the Holders of any Warrant Stock issued upon the exercise of this Warrant from and against any and all liability, loss, cost,
damage, reasonable attorneys’ and accountants’ fees and expenses, court costs and all other out-of-pocket expenses
incurred in connection with or arising from any default hereunder by the Company or the enforcement of its rights hereunder as
against the Company. This indemnification provision shall be in addition to the rights of such Holder or Holders to bring an action
against the Company for breach of contract based on such default hereunder.

11.4            
Limitation of Liability. No provision hereof, in the absence of affirmative action by the Holder to purchase shares
of Warrant Stock, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of such
Holder to pay the Exercise Price for any Warrant Stock other than pursuant to an exercise of this Warrant or any liability as a
stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. The Holder shall
not, by virtue hereof, be entitled to any rights of a stockholder of the Company and nothing contained in this Warrant shall be
construed as conferring upon the Holder the right to vote or to consent or to receive notice as a stockholder in respect of meetings
of stockholders for the election of directors of the Company or any other matters or any rights whatsoever as a stockholder of
the Company.

11.5            
Remedies. The Holder of the Warrant and/or Warrant Stock, in addition to being entitled to exercise its rights granted
by law, including recovery of damages, shall be entitled to specific performance of its rights provided under this Warrant. The
Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the
provisions of this Warrant and hereby agrees, in an action for specific performance, to waive the defense that a remedy at law
would be adequate.

11.6            
Successors and Assigns. This Warrant and the rights evidenced hereby shall inure to the benefit of and be binding
upon the successors of the Company and the permitted successors and assigns of the Holder. The provisions of this Warrant are intended
to be for the benefit of all Holders from time to time of this Warrant and to the extent applicable, all Holders of shares of Warrant
Stock issued upon the exercise hereof (including transferees), and shall be enforceable by any such Holder.

11.7            
Amendment. The prior written consent of the Company and the Required Holders shall be required for any change, waiver
or amendment to this Warrant. Any change, waiver or amendment so approved shall be binding upon all existing and future holders
of this Warrant and any other Fifth Amendment Warrants; provided, however, that no such change, waiver or amendment,
as applied to any of the Fifth Amendment Warrants held by any particular holder of Fifth Amendment Warrants, shall, without the
written consent of that particular holder, (i) disproportionately and materially adversely affect any rights under such particular
holder’s Fifth Amendment Warrant (other than as reflected by the different number of shares of Warrant Stock issuable to
such holder); or (ii) modify any of the provisions of, or impair the right of any holder of Fifth Amendment Warrants under, this
Section 11.7. This Warrant cannot be changed, modified, discharged or terminated by oral agreement.

11.8            
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision
or the remaining provisions of this Warrant.

11.9            
Headings. The headings and other captions in this Warrant are for the convenience and reference only and shall not
be used in interpreting, construing or enforcing any provision of this Warrant.

    	 	17	 

     

    

 

11.10        
Governing Law. IN ALL RESPECTS, INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, THIS WARRANT
SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT
OF LAW PRINCIPLES AND ANY APPLICABLE LAWS OF THE UNITED STATES OF AMERICA.

11.11        
Jurisdiction. Each of the Company and the Holder hereby irrevocably and unconditionally submits for itself and its
property in any legal action or proceeding relating to this Warrant, or for recognition and enforcement of any judgment in respect
thereof, to the exclusive general jurisdiction of the courts of the Supreme Court of the State of New York sitting in New York
County, the courts of the United States for the Southern District of New York, and appellate courts from any thereof, consents
that any such action or proceeding may be brought in such courts and waives any objection that it may now or hereafter have to
the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court
and agrees not to plead or claim the same, agrees that service of process in any such action or proceeding may be effected by delivery
of notice pursuant to Section 11.2 hereof and agrees that nothing herein shall affect the right to effect service of process in
any other manner permitted by law.

11.12        
Waiver of Jury Trial. EACH OF THE COMPANY AND THE HOLDER WAIVES ANY RIGHT TO TRIAL BY JURY ON ANY CLAIM, DEMAND,
ACTION OR CAUSE OF ACTION (A) ARISING UNDER THIS WARRANT OR (B) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THIS WARRANT
OR THE TRANSACTIONS RELATED HERETO, IN EACH CASE WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE. EACH OF THE COMPANY AND THE
HOLDER AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY,
AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS CLAUSE WITH ANY COURT AS WRITTEN EVIDENCE
OF THE CONSENT OF THE COMPANY AND THE HOLDER TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH OF THE COMPANY AND THE HOLDER
ACKNOWLEDGES THAT IT HAS HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL REGARDING THIS SECTION 11.12, THAT IT FULLY UNDERSTANDS ITS
TERMS, CONTENT AND EFFECT, AND THAT IT VOLUNTARILY AND KNOWINGLY AGREES TO THE TERMS OF THIS SECTION 11.12.

11.13        
Entire Agreement. This Warrant contains the entire agreement with respect to the subject matter hereof and supersedes
and replaces all other prior agreements, written or oral, with respect to the subject matter hereof.

11.14        
Originals. A signed copy of this Warrant delivered by facsimile, e-mail or other means of electronic transmission
shall be deemed to have the same legal effect as delivery of an original copy of this Warrant.

[Execution Page Follows]

    	 	18	 

     

    

IN WITNESS WHEREOF, the Company has caused
this Warrant to be duly executed as of the Original Issue Date.

 

	 	CADIZ INC.
	 	 
	 	By: 	/s/ Timothy J. Shaheen
	 	 	Name:Timothy J. Shaheen
Title:CFO

 

    	 	19	 

     

    

ANNEX A TO THE WARRANT

EXERCISE NOTICE

[To be executed only upon exercise of Warrant]

The undersigned registered owner of this
Warrant irrevocably exercises this Warrant for the purchase of ______ shares of Common Stock of Cadiz Inc. and herewith makes payment
therefor in __________, all at the price and on the terms and conditions specified in this Warrant and requests that the shares
of Common Stock hereby purchased (and any securities or other property issuable upon such exercise) be issued in the name of, and
delivered to, as applicable, _________________, whose address is __________________________________ ____________________________________________________________________,
and, if such shares of Common Stock shall not include all of the shares of Common Stock issuable as provided in this Warrant, that
a new Warrant of like tenor and date for the balance of the shares of Common Stock issuable hereunder be delivered to the undersigned.

TO DELETE THE FOLLOWING BRACKETED LANGUAGE
IF INAPPLICABLE AT EXERCISE DATE:[The undersigned hereby notifies Cadiz Inc. that a Holder Group would beneficially own a number
of shares of Common Stock in excess of the Beneficial Ownership Limitation set forth in this Warrant upon giving effect to this
Exercise Notice. Pursuant to such limitation, Cadiz Inc. shall give effect to this Exercise Notice in accordance with such limitation
as of [INSERT DATE], the date hereof].

_______________________________

(Name of Registered Owner)

_______________________________

(Signature of Registered Owner)

_______________________________

(Street Address)

_______________________________

(City) (State) (Zip Code)

	 	 
	NOTICE:	The signature on this Exercise Notice must correspond with the name as written upon the face of the within Warrant in every particular, without alteration or enlargement or any change whatsoever.

 

    	 	20	 

     

    

 

ANNEX B TO THE WARRANT

ASSIGNMENT FORM

FOR VALUE RECEIVED the undersigned registered
owner of this Warrant hereby assigns unto the assignee named below all of the rights of the undersigned under this Warrant, with
respect to the number of shares of Common Stock set forth below:

	
        Name and Address of Assignee
	 	
        No. of Shares of Common Stock

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

and does hereby irrevocably constitute and appoint ________
_____________ attorney-in-fact to register such transfer onto the books of Cadiz Inc. maintained for the purpose, with full power
of substitution in the premises.

	Dated:	Print Name:
	 	 
	Signature:	Witness
	 	 
	 	 
	NOTICE:	The signature on this assignment must correspond with the name as written upon the face of the within Warrant in every particular, without alteration or enlargement or any change whatsoever.
	 	 	 

 

    	 	21Exhibit 4.2

 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	WARRANT
	 
	to
    Purchase Common Stock of
	 
	Cadiz
    Inc.
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	Warrant
    No. A-2
	Original
    Issue Date:  November 29, 2016

 

     

     

    

 

THE SECURITIES REPRESENTED
BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SECURITIES IS EFFECTIVE UNDER
THE SECURITIES ACT OR (II) THE TRANSACTION IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES
LAWS.

Original
Issue Date: November 29, 2016Warrant No. A-2

Warrant

to
Purchase 39,409 Shares (Subject to Adjustment) of Common Stock of

Cadiz
Inc.

THIS IS TO
CERTIFY THAT MILFAM II L.P. (“Investor”), or its registered assigns,
is entitled, at any time prior to the Expiration Date to purchase from Cadiz Inc., a Delaware corporation (the “Company”),
39,409 shares (subject to adjustment as provided herein) of the common stock, par value $0.01 per share, of the Company at a purchase
price of $0.01 per share (the initial “Exercise Price,” subject to
adjustment as provided herein).

This Warrant
was issued in connection with that certain Fifth Amendment to Amended and Restated Credit Agreement (the “Fifth Amendment”),
dated as of November 29, 2016 (the “Fifth Amendment Effective Date”), by and among the Company, as a borrower,
Cadiz Real Estate LLC, as a borrower, Investor, as a lender, the other lenders party thereto, and Wells Fargo Bank, National Association,
as agent (the “Agent”), which amended that certain Amended and Restated Credit Agreement (as amended through
and including the Fifth Amendment Effective Date, and as subsequently amended from time to time, the “Credit Agreement”)
attached to that certain Amendment Agreement, dated as of October 30, 2013, by and among the Company, Cadiz Real Estate LLC, LC
Capital Master Fund, Ltd., the lenders party thereto, and the Agent, and is subject to the terms thereof.

		1.	DEFINITIONS

As used
in this Warrant, the following terms have the respective meanings set forth below, and to the extent such terms have the respective
meaning set forth in the Credit Agreement, such terms shall have such meaning as set forth in the Credit Agreement, provided,
however, that if such Credit Agreement is expired, terminated or otherwise discharged, such terms shall have the meaning
set forth in the Credit Agreement immediately prior to such expiration, termination or discharge:

“10-Day
VWAP” shall have the meaning ascribed to such term in the Credit Agreement.

“Affiliate”
of, or a Person “Affiliated” with, a specified Person means any other
Person directly or indirectly controlling, controlled by, or under common control with, that Person. For the purposes of this
definition, “control” (including, with correlative meanings, the terms “controlling,” “controlled
by” and “under common control with”), as applied to any Person, means the possession, directly or indirectly,
of the power (i) to vote 5% or more of the securities having ordinary voting power for the election of directors of such Person,
or (ii) to direct or cause the direction of the management and policies of that Person, whether through the ownership of voting
securities or by contract or otherwise.

    1 

     

    

 

“Agent”
shall have the meaning set forth in the preamble to this Warrant.

“Aggregation
Date” shall have the meaning set forth in Section 5.2 hereof.

“Applicable
Rate” shall have the meaning ascribed to such term in the Credit Agreement.

“Appraisal
Procedure” means the following procedure to determine the fair market value, as to any security, for purposes
of the definition of “Fair Market Value” or the fair market value,
as to any other property (in either case, the “Valuation Amount”).
The Valuation Amount shall be determined in good faith jointly by the Company and the Holder; provided, however,
that if such parties are not able to agree on the Valuation Amount within a reasonable period of time (not to exceed twenty (20)
Business Days), the Valuation Amount shall be determined by the mutual agreement of two (2) independent appraisers, one appointed
by the Company and one appointed by the Holder, with each appointed within ten (10) days of the Appraisal Procedure having been
first invoked by the Holder. The Company and the Holder shall submit their respective valuations and other relevant data to the
appraisers, and the appraisers shall, within twenty (20) days of the later of the two appraisers’ appointment dates, mutually
agree to a determination of the Valuation Amount. If such appraisers cannot mutually agree on the Valuation Amount by such date,
a third independent appraiser shall be chosen within 10 days of such date by the mutual consent of the first two appraisers. Such
third appraiser shall make a determination of the Valuation Amount within twenty (20) days of its appointment. If three (3) appraisers
shall have been appointed and made determinations of the Valuation Amount, then the average of the three (3) Valuation Amounts
shall be final and binding on the Company and the Holder as the final Valuation Amount, provided, however, that
if the determination of one appraiser differs by an amount equal to more than twice that of the middle of the three appraisers’
Valuation Amounts (the “Outlier Appraiser”), then the determination of the Outlier Appraiser shall be excluded
from determining the final Valuation Amount and the remaining two appraisers’ determinations of the Valuation Amount shall
be averaged and such average shall be final and binding upon the Company and the Holder as the final Valuation Amount. The Company
shall pay all of the fees and expenses incurred in conducting the Appraisal Procedure.

“beneficial
owner” and “beneficially own” shall have the meaning set forth under Section 13(d) of the Exchange
Act.

“Beneficial
Ownership Limitation” has the meaning set forth in Section 5.1 hereof.

“Business
Day” shall have the meaning ascribed to such term in the Credit Agreement.

“Closing
Share and Warrant Issuance Agreement” means that certain Closing Share and Warrant Issuance Agreement by and between
the Company and the Investor, dated November 29, 2016.

“Commission”
means the Securities and Exchange Commission or any other federal agency then administering the Securities Act and other federal
securities laws.

    2 

     

    

 

“Common
Stock” means the common stock, par value $0.01 per share, of the Company as constituted on the Original Issue
Date, and any capital stock into which such Common Stock may thereafter be changed, and shall also include (i) capital stock of
the Company of any other class (regardless of how denominated) issued to the holders of shares of any Common Stock upon any reclassification
thereof which is also not preferred as to dividends or liquidation over any other class of stock of the Company and which is not
subject to redemption and (ii) shares of common stock of any successor or acquiring corporation received by or distributed to
the holders of Common Stock of the Company in the circumstances contemplated by Section 4.6 hereof.

“Company”
shall have the meaning set forth in the preamble to this Warrant.

“Credit
Agreement” shall have the meaning set forth in the preamble to this Warrant.

“Delivery
Notice” shall have the meaning set forth in Section 5.1(c) hereof.

“Designated
Office” shall have the meaning set forth in Section 9 hereof.

“Dilution
Adjustment” shall have the meaning set forth in Section 10.1(a) hereof.

“Dilution
Price” shall mean, with respect to each share of Common Stock, $9.05, subject to adjustments described in Sections
4.4, 4.5 and 4.6 hereof.

“DOJ”
shall have the meaning set forth in Section 6.4 hereof.

“DTC”
shall have the meaning set forth in Section 2.1(b) hereof.

“DWAC”
shall have the meaning set forth in Section 2.1(b) hereof.

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated
thereunder, all as the same shall be in effect at the time.

“Exercise
Date” shall have the meaning set forth in Section 2.1(a) hereof.

“Exercise
Notice” shall have the meaning set forth in Section 2.1(a) hereof.

“Exercise
Price” means, in respect of a share of Warrant Stock at any date herein specified, the initial Exercise Price
set forth in the preamble of this Warrant, as adjusted from time to time pursuant to Article 4 hereof.

“Expiration
Date” means (i) the fifth anniversary of the Original Issue Date, to be extended to allow for delayed exercise
and delivery of any Warrant Stock in accordance with Section 5.1(c) hereof, or (ii) if, at the Initial Exercise Date and pursuant
to Section 2.1(a) hereof, the Warrant does not become exercisable because no principal or interest amounts are outstanding under
the Credit Agreement, the Initial Exercise Date.

“Expiration
Warrant Stock” shall have the meaning set forth in Section 5.1(c) hereof.

    3 

     

    

 

“Fair
Market Value” means (i) as to any Common Stock listed or quoted on a Trading Market, the 10-Day VWAP determined
in respect of such primary Trading Market and (ii) as to any Common Stock not listed or quoted on a Trading Market or any other
security, (A) the Ten Day Average of the average closing prices of such security’s sales on all domestic securities exchanges
on which such security may at the time be listed, or (B) if there have been no sales on any such exchange such that the foregoing
Ten Day Average cannot be calculated, the average of the highest bid and lowest asked prices on all such exchanges at the end
of the Business Day immediately prior to the date that Fair Market Value is determined as of, or (C) if on any day such security
is not listed any domestic securities exchange such that neither the foregoing Ten Day Average nor the foregoing bid-and-asked
price average can be calculated, the average of the highest bid and lowest asked prices at the end of the Business Day immediately
prior to the date that Fair Market Value is determined as of in the domestic over-the-counter market as reported by the National
Association of Securities Dealers Automated Quotation System or similar organization (and in each such case excluding any trades
that are not bona fide, arm’s length transactions). If neither the foregoing clause (i) nor clause (ii) is applicable, then
(i) the “Fair Market Value” of such security as of an applicable determination date shall be as determined in good
faith by the Board of Directors of the Company, provided, however, that if shares of such security have been sold
in arms-length transactions by the Company within the 90-day period prior to the determination of the Fair Market Value, the Fair
Market Value determined pursuant to this sentence shall not be less than the highest price paid for such shares during such period,
and (ii) with respect to property other than securities, the “Fair Market Value” of such other property on the applicable
determination date shall be as determined in good faith by the Board of Directors of the Company.

“Fifth
Amendment” shall have the meaning set forth in the preamble to this Warrant.

“Fifth
Amendment Effective Date” shall have the meaning set forth in the preamble
to this Warrant.

“Fifth
Amendment Warrants” means the Warrant together with all other warrants issued pursuant to the Fifth Amendment.

“FTC”
shall have the meaning set forth in Section 6.4 hereof.

“Governmental
Authority” shall have the meaning set forth in the Credit Agreement.

“Holder”
means with respect to any Warrant or share of Warrant Stock, the Person in whose name the Warrant or Warrant Stock is registered
on the books of the Company maintained for such purpose.

“Holder
Group” shall have the meaning set forth in Section 5.1(d) hereof.

“HSR
Act” shall have the meaning set forth in Section 6.4 hereof.

“Initial
Exercise Date” shall have the meaning set forth in Section 2.1(a) hereof.

“Interest
Share Issuance” shall have the meaning set forth in the Credit Agreement.

    4 

     

    

 

“Investor”
shall have the meaning set forth in the preamble to this Warrant.

“Lien”
means (i) any lien, mortgage, pledge, assignment, security interest, charge or encumbrance of any kind (including any agreement
to give any of the foregoing, any conditional sale or other title retention agreement, and any lease in the nature thereof) and
any option, trust or other preferential arrangement having the practical effect of any of the foregoing, and (ii) in the case
of securities, any purchase option, call or similar right of a third party with respect to such securities.

“Maximum
Percentage” shall have the meaning set forth in Section 5.1 hereof.

“Original
Issue Date” means November 29, 2016, the date on which the Original Warrant was issued by the Company pursuant
to the Closing Share and Warrant Issuance Agreement and the Fifth Amendment.

“Original
Warrant” means the Warrant as originally issued by the Company pursuant to the Closing Share and Warrant Issuance
Agreement and the Fifth Amendment.

“Outlier
Appraiser” shall have the meaning set forth in Article 1 hereof.

“Outstanding”
means, subject to Section 5.1(d) hereof, when used with reference to Common Stock, at any date as of which the number of shares
thereof is to be determined, all issued and actually outstanding shares of Common Stock, except shares then owned or held by or
for the account of the Company or any Subsidiary, and shall include all shares issuable in respect of outstanding scrip or any
certificates representing fractional interests in shares of Common Stock.

“Person”
means and includes natural persons, corporations, limited partnerships, general partnerships, limited liability companies, limited
liability partnerships, joint stock companies, joint ventures, associations, companies, trusts, banks, trust companies, land trusts,
business trusts or other organizations, whether or not legal entities, and Governmental Authority.

“Reference
Price” shall have the meaning set forth in Section 4.1 hereof.

“Related
Issuances” shall have the meaning set forth in Section 5.2 hereof.

“Required
Holders” means holders of outstanding Fifth Amendment Warrants representing more than 50% of the Warrant Stock issuable
upon exercise of such outstanding Fifth Amendment Warrants.

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated
thereunder, all as the same shall be in effect at the time.

“Stockholder
Approval” means the approval by the stockholders of the Company for purposes of terminating the issuance cap in respect
of shares of Common Stock set forth in Section 5.2 hereof.

    5 

     

    

 

“Subsidiary”
means any corporation, association, trust, limited liability company, partnership, joint venture or other business association
or entity (i) at least 50% of the Outstanding voting securities of which are at the time owned or controlled, directly or indirectly,
by the Company; or (ii) with respect to which the Company possesses, directly or indirectly, the power to direct or cause the
direction of the affairs or management of such Person.

“Ten
Day Average” means, with respect to any prices and in connection with the calculation of Fair Market Value, the
average of such prices over the ten Business Days ending on the Business Day immediately prior to the day as of which “Fair
Market Value” is being determined.

“Trading
Day” means any day that the primary Trading Market on which the Common Stock is listed or quoted is open for trading.

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

“Transfer
Agent” shall have the meaning set forth in Section 2.1(b) hereof.

“Valuation
Amount” shall have the meaning set forth in Article 1 hereof.

“Warrant
Price” means an amount equal to (i) the number of shares of Warrant Stock being purchased upon exercise of this
Warrant pursuant to Section 2.1 hereof, multiplied by (ii) the Exercise Price.

“Warrant”
means the Original Warrant and all warrants issued upon transfer, division or combination of, or in substitution for, the Original
Warrant, or any other like warrant subsequently issued to the Holder. All such foregoing warrants shall at all times be identical
as to terms and conditions, except as to the number of shares of Warrant Stock for which they may be exercised and their date
of issuance.

“Warrant
Stock” means the shares of Common Stock issued, issuable or both (as the context may require) upon the exercise
of the Warrant.

		2.	EXERCISE
                                         OF WARRANT

2.1                
Manner of Exercise.

(a)               
If any principal or interest amounts are outstanding under the Credit Agreement on the date that is the one hundred and
eightieth (180th) day following the Fifth Amendment Effective Date (the foregoing 180th day, the “Initial
Exercise Date”), then from the Initial Exercise Date and at any time before 4:00 P.M., Eastern Standard Time,
on the Expiration Date, the Holder of this Warrant may from time to time exercise this Warrant, on any Business Day, for all or
any part of the number of shares of Warrant Stock (subject to adjustment as provided herein) purchasable hereunder. In order to
exercise this Warrant, in whole or in part, the Holder shall (i) deliver to the Company at its Designated Office a written notice
of the Holder’s election to exercise this Warrant (an “Exercise Notice”)
substantially in the form attached to this Warrant as Annex A, which Exercise Notice shall be irrevocable and specify the
number of shares of Warrant Stock to be purchased, together with this Warrant and (ii) pay to the Company the Warrant Price. The
date on which such delivery and payment shall have taken place being hereinafter referred to as the “Exercise
Date.” If at the Expiration Date, this Warrant remains exercisable for any Warrant Stock, the Holder shall be
deemed to have delivered an Exercise Notice for such remaining Warrant Stock as of the Expiration Date and payment for such Warrant
Stock shall be deemed to be made by the Holder pursuant to Section 2.1(c)(i) hereof, unless the Holder notifies the Company otherwise
prior to the Expiration Date in respect of such delivery and payment. For the avoidance of doubt, once this Warrant shall become
exercisable in accordance with this Section 2.1, any subsequent payment of all remaining principal and interest outstanding under
the Credit Agreement shall not affect the ability of the Holder to exercise this Warrant.

    6 

     

    

 

(b)              
Subject to Article 5 hereof, upon receipt by the Company of such Exercise Notice, surrender of this Warrant and payment
of the Warrant Price (in accordance with Section 2.1(c) hereof), the Company shall cause its Transfer Agent to deliver the applicable
shares of Warrant Stock, and the Company shall deliver or cause to be delivered cash in lieu of any fraction of a share, to the
Holder and register such issued shares of Warrant Stock on the books of the Company as instructed by the Holder in the Exercise
Notice. The issued shares of Warrant Stock will be delivered by crediting the account of the Holder’s prime broker (as specified
by the Holder to the Company) with the Depository Trust Company (“DTC”)
through its Deposit/Withdrawal At Custodian (“DWAC”) system, whereby
the Holder’s prime broker shall initiate a DWAC transaction no later than 4:00 p.m. Eastern Standard Time on the third Trading
Day following the Exercise Date using its DTC participant identification number, and released by Continental Stock Transfer &
Trust Company, the Company’s transfer agent (the “Transfer Agent”),
at the Company’s direction. The Holder shall direct the broker-dealer at which the account or accounts to be credited with
the issued shares of Warrant Stock are maintained, which broker/dealer shall be a DTC participant, to initiate a transaction through
the DWAC system, instructing the Transfer Agent to credit such account or accounts with such shares of Warrant Stock. Such DWAC
instruction shall indicate the settlement date for the deposit of such shares of Warrant Stock, which shall be the Exercise Date.
The Company shall direct the Transfer Agent to credit the Holder’s account or accounts with such shares of Warrant Stock
pursuant to the information contained in the DWAC instruction. This Warrant shall be deemed to have been exercised and such shares
of Warrant Stock shall be deemed to have been issued, and the Holder or any other Person so designated to be named therein shall
be deemed to have become a holder of record of such shares of Warrant Stock for all purposes, as of the Exercise Date.

(c)               
Subject to Article 5 hereof, payment of the Warrant Price shall be made at the option of the Holder by one or more of the
following methods: (i) by delivery of a certified or official bank check or by wire transfer of immediately available funds in
the amount of such Warrant Price payable to the order of the Company, (ii) by instructing the Company to withhold a number of
shares of Warrant Stock then issuable upon exercise of this Warrant with an aggregate Fair Market Value equal to such Warrant
Price, (iii) by surrendering to the Company shares of Common Stock previously acquired by the Holder with an aggregate Fair Market
Value equal to such Warrant Price, or (iv) any combination of the foregoing. In the event of any withholding of Warrant Stock
or surrender of Common Stock pursuant to clause (ii), (iii) or (iv) of this Section 2.1(c) where the number of shares whose Fair
Market Value is equal to the Warrant Price is not a whole number, the number of shares withheld by or surrendered to the Company
shall be rounded up to the nearest whole share and the Company shall make a cash payment to the Holder based on the incremental
fraction of a share being so withheld by or surrendered to the Company in an amount determined in accordance with Section 2.3
hereof. The Holder will receive fully paid and nonassessable shares of Warrant Stock upon any exercise of this Warrant.

    7 

     

    

 

(d)              
If this Warrant shall have been exercised in part, the Company shall, at the time of delivery of the shares of Warrant
Stock being issued in accordance with Section 2.1(c) hereof, deliver to the Holder a new Warrant evidencing the rights of the
Holder to purchase the unpurchased shares of Warrant Stock called for by this Warrant. Such new Warrant shall in all other respects
be identical to this Warrant.

(e)               
Subject to Section 2.1(d) hereof, the Warrant delivered for exercise, and properly exercised by the Holder, in accordance
with Sections 2.1(a)-(c) and Article 5 hereof shall be canceled by the Company.

2.2                
Payment of Taxes. All shares of Warrant Stock issuable upon the exercise of this Warrant pursuant to the terms hereof
shall be validly issued, fully paid and nonassessable, issued without violation of any preemptive or similar rights of any stockholder
of the Company and free and clear of all Liens. The Company shall pay all expenses in connection with, and all taxes and other
governmental charges that may be imposed with respect to, the issue or delivery thereof.

2.3                
Fractional Shares. The Company shall not be required to issue a fractional share of Warrant Stock upon exercise
of the Warrant. As to any fraction of a share that the Holder of the Warrant, the rights under which are exercised in the same
transaction, would otherwise be entitled to purchase upon such exercise, the Company shall pay to such Holder an amount in cash
equal to such fraction multiplied by the Fair Market Value of one share of Common Stock on the Exercise Date.

		3.	TRANSFER, DIVISION AND COMBINATION

3.1                
Transfer. Upon compliance with the provisions of this Section 3.1, each transfer of this Warrant and all rights
hereunder, in whole or in part, shall be registered on the books of the Company to be maintained for such purpose, upon surrender
of this Warrant at the Designated Office and compliance with the terms hereof, together with a written assignment of this Warrant
in the form of Annex B attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes described in Section 2.2 hereof in connection with the making of such transfer. Upon such compliance, surrender
and delivery and, if required, such payment, the Company shall execute and deliver a new Warrant in the name of the assignee or
assignees and in the denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned and this Warrant shall promptly be cancelled.

3.2                
Mutilation or Loss. Upon receipt by the Company from any Holder of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant and an indemnity reasonably satisfactory to it (it being understood that
the written indemnification agreement of or affidavit of loss of the Holder shall be a sufficient indemnity) and, in case of mutilation,
upon surrender and cancellation hereof, the Company will execute and deliver in lieu hereof a new Warrant of like tenor to such
Holder; provided, however, that, in the case of mutilation, no indemnity shall be required if this Warrant in identifiable
form is surrendered to the Company for cancellation.

    8 

     

    

 

3.3                
Division and Combination. Subject to compliance with the applicable provisions of this Warrant, this Warrant may
be divided or, following such division, combined with other Warrants upon presentation hereof at the Designated Office, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its
agent or attorney. Subject to compliance with the applicable provisions of this Warrant as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice.

3.4                
Expenses. The Company shall prepare, issue and deliver at its own expense any new Warrant or Warrants required to
be issued hereunder.

3.5                
Maintenance of Books. The Company agrees to maintain, at the Designated Office, books for the registration and transfer
of the Warrants.

3.6                
Registration of Warrant Stock. Notwithstanding any termination, amendment, modification or supplement of the Credit
Agreement subsequent to the date hereof or, following the Initial Exercise Date, any subsequent payment of all remaining principal
and interest outstanding under the Credit Agreement, Section 2.4(h) of the Credit Agreement is hereby incorporated by reference
herein as if fully set forth herein as of the date hereof and shall apply mutatis mutandis to this Warrant and the Warrant
Stock.

		4.	ANTIDILUTION
                                         PROVISIONS

The number
of shares of Warrant Stock for which this Warrant is exercisable and the Exercise Price shall be subject to adjustment from time
to time as set forth in this Article 4.

4.1                
Upon Issuance of Common Stock. If the Company shall, at any time or from time to time after the Original Issue Date,
issue any shares of Common Stock, options to purchase or rights to subscribe for Common Stock, securities by their terms convertible
into or exchangeable for Common Stock, or options to purchase or rights to subscribe for such convertible or exchangeable securities
without consideration or for consideration per share less than the greater of (x) the Dilution Price in effect immediately prior
to the issuance of such Common Stock or securities and (y) the Fair Market Value per share of the Common Stock immediately prior
to such issuance (the greater of (x) and (y), the “Reference Price”), then such Exercise Price shall forthwith
be lowered to a price equal to the price obtained by multiplying:

(i)                
the Exercise Price in effect immediately prior to the issuance of such Common Stock, options, rights or securities by

    9 

     

    

(ii)              
a fraction of which (x) the numerator shall be the sum of (i) the number of shares of Common Stock Outstanding immediately
prior to such issuance and (ii) the number of additional shares of Common Stock which the aggregate consideration for the number
of shares of Common Stock so offered would purchase at the Reference Price and (y) the denominator shall be the number of shares
of Common Stock Outstanding immediately after such issuance.

4.2                
Upon Acquisition of Common Stock. If the Company or any Subsidiary shall, at any time or from time to time after
the Original Issue Date, directly or indirectly, redeem, purchase or otherwise acquire any shares of Common Stock, options to
purchase or rights to subscribe for Common Stock, securities by their terms convertible into or exchangeable for Common Stock,
or options to purchase or rights to subscribe for such convertible or exchangeable securities, for a consideration per share (plus,
in the case of such options, rights, or securities, the additional consideration required to be paid to the Company upon exercise,
conversion or exchange) greater than the Fair Market Value per share of Common Stock immediately prior to the earlier of (x) the
announcement of such event or (y) such event, then the Exercise Price shall forthwith be lowered to a price equal to the price
obtained by multiplying:

(i)                
the Exercise Price in effect immediately prior to such event by

(ii)              
a fraction:

		(A)	the numerator of which is (1)
                                         the product of (a) the number of shares of Common Stock Outstanding and (b) the Fair
                                         Market Value per share of Common Stock, in each case immediately prior to such event,
                                         minus (2) the aggregate consideration paid by the Company in such event (plus, in the
                                         case of such options, rights, or convertible or exchangeable securities, the aggregate
                                         additional consideration required to be paid to the Company upon exercise, conversion
                                         or exchange), and

		(B)	the denominator of which is the
                                         product (1) the number of shares of Common Stock Outstanding immediately after such event
                                         and (2) the Fair Market Value per share of Common Stock immediately prior to such event.

4.3                
Provisions Applicable to Adjustments. For the purposes of any adjustment of the Exercise Price pursuant to Section
4.1 or 4.2 hereof, the following provisions shall be applicable:

(i)                
In the case of the issuance of Common Stock, options to purchase or rights to subscribe for Common Stock, securities by
their terms convertible into or exchangeable for Common Stock, or options to purchase or rights to subscribe for such convertible
or exchangeable securities for a consideration in whole or in part other than cash, the consideration other than cash shall be
deemed to be the Fair Market Value of the non-cash consideration.

(ii)              
In the case of the issuance of options to purchase or rights to subscribe for Common Stock, securities by their terms convertible
into or exchangeable for Common Stock, or options to purchase or rights to subscribe for such convertible or exchangeable securities:

    10 

     

    

		(A)	the aggregate maximum number
                                         of shares of Common Stock that potentially may be deliverable upon exercise of such options
                                         to purchase or rights to subscribe for Common Stock at any time during the term thereof
                                         shall be deemed to have been issued at the time such options or rights were issued and
                                         for a consideration equal to the consideration (determined in the manner provided in
                                         subparagraph (i) above), if any, received by the Company upon the issuance of such options
                                         or rights plus the minimum purchase price provided in such options or rights for the
                                         Common Stock covered thereby;

		(B)	the aggregate maximum number
                                         of shares of Common Stock that potentially may be deliverable upon conversion of or in
                                         exchange for any such convertible or exchangeable securities or upon the exercise of
                                         options to purchase or rights to subscribe for such convertible or exchangeable securities
                                         and subsequent conversion or exchange thereof at any time during the term thereof shall
                                         be deemed to have been issued at the time such securities, options, or rights were issued
                                         and for a consideration equal to the consideration received by the Company for any such
                                         securities and related options or rights (excluding any cash received on account of accrued
                                         interest or accrued dividends), plus the additional consideration, if any, to be received
                                         by the Company upon the conversion or exchange of such securities or the exercise of
                                         any related options or rights (the consideration in each case to be determined in the
                                         manner provided in paragraph (i) above);

		(C)	on any increase in the number
                                         of shares or decrease in the effective exercise or conversion price of Common Stock deliverable
                                         upon exercise of any such options, rights or securities or conversions of or exchanges
                                         of such securities, including any change resulting from the anti-dilution provisions
                                         thereof, the Exercise Price shall forthwith be readjusted to such Exercise Price as would
                                         have been obtained had the adjustment made upon the issuance of such options, rights
                                         or securities not converted prior to such change or options or rights related to such
                                         securities not converted prior to such change been made upon the basis of such change;
                                         and

		(D)	no further adjustment of the
                                         Exercise Price adjusted upon the issuance of any such options, rights, convertible securities
                                         or exchangeable securities shall be made as a result of the actual issuance of Common
                                         Stock on the exercise of any such rights or options or any conversion or exchange of
                                         any such securities.

    11 

     

    

 

4.4                
Upon Stock Dividends, Subdivisions or Splits. If, at any time after the Original Issue Date, the number of shares
of Common Stock Outstanding is increased by a stock dividend payable in shares of Common Stock or by a subdivision or split-up
of shares of Common Stock, then, following the record date for the determination of holders of Common Stock entitled to receive
such stock dividend, or to be affected by such subdivision or split-up, the Exercise Price and the Dilution Price shall each be
appropriately decreased by multiplying each price by a fraction, the numerator of which is the number of shares of Common Stock
Outstanding immediately prior to such increase and the denominator of which is the number of shares of Common Stock Outstanding
immediately after such increase in Outstanding shares.

4.5                
Upon Combinations or Reverse Stock Splits. If, at any time after the Original Issue Date, the number of shares of
Common Stock Outstanding is decreased by a combination or reverse stock split of the Outstanding shares of Common Stock into a
smaller number of shares of Common Stock, then, following the record date to determine shares affected by such combination or
reverse stock split, the Exercise Price and the Dilution Price shall each be appropriately increased by multiplying each price
by a fraction, the numerator of which is the number of shares of Common Stock Outstanding immediately prior to such decrease and
the denominator of which is the number of shares of Common Stock Outstanding immediately after such decrease in Outstanding shares.

4.6                
Upon Reclassifications, Reorganizations, Consolidations, Mergers or Dispositions of Assets. In the event of any
capital reorganization of the Company, any reclassification of the capital stock of the Company (other than a change in par value
or from par value to no par value or from no par value to par value or as a result of a stock dividend or subdivision, stock-split,
reverse stock-split or combination of shares), any consolidation or merger of the Company with or into another Person (where the
Company is not the surviving Person or where there is a change in or distribution with respect to the Common Stock) or sale, transfer
or other disposition of all or substantially all of the Company’s property, assets or business to another Person, each Warrant
shall after such reorganization, reclassification, consolidation, merger or disposition of assets be exercisable for the kind
and number of shares of stock or other securities or property of the Company or of the successor Person (if other than the Company)
resulting from such reorganization, reclassification, consolidation, merger or disposition of assets, if any, to which the holder
of the number of shares of Common Stock deliverable (immediately prior to the time of such reorganization, reclassification, consolidation,
merger or disposition of assets) upon exercise of such Warrant would have been entitled upon such reorganization, reclassification,
consolidation, merger or disposition of assets (without taking into account any limitations or restrictions on the exercisability
of this Warrant); and, in such case, appropriate adjustment (in form and substance satisfactory to the Holder) shall be made with
respect to the Holder’s rights under this Warrant to insure that the provisions of Article 4 hereof shall thereafter be
applicable, as nearly as possible, to this Warrant in relation to any shares of stock, securities or assets thereafter acquirable
upon exercise of this Warrant (and, for the avoidance of doubt, such adjustments shall include any appropriate adjustment to the
Dilution Price to realize the intended economic protection to the Holder of Section 4.1 hereof, as appropriate). The Company shall
not effect any such reorganization, reclassification, consolidation, merger or disposition of assets unless, prior to the consummation
thereof, the successor Person (if other than the Company) resulting from such reorganization, reclassification, consolidation,
merger or disposition of assets, shall assume, by written instrument, the obligation to deliver to the Holders of the Warrant
such shares of stock, securities or assets, which, in accordance with the foregoing provisions of this Section 4.6, such Holders
shall be entitled to receive upon such conversion. The provisions of this Section 4.6 shall similarly apply to successive reorganizations,
reclassifications, consolidations, mergers or dispositions of assets.

4.7                
Other Anti-Dilution Provisions. If the Company has issued or issues any securities of the Company to a financial
institution, lender, other credit provider, leasing company or other lessor in connection with the provisions of any financing
or lending agreements, containing provisions (including, without limitation, any of the terms of pricing, exercise price, anti-dilution
and registration rights) which are more favorable than those set forth herein, the Company will make such provisions (or any more
favorable portion thereof) available to the Holder and will enter into amendments necessary to confer such rights on the Holder.

    12 

     

    

4.8                
Appraisal Procedure. In any case in which the provisions of this Article 4 shall necessitate that the Appraisal
Procedure be utilized for purposes of determining an adjustment to the Exercise Price, the Company may defer, until the completion
of the Appraisal Procedure and the determination of the adjustment, (i) issuing to the Holder of any Warrant exercised after the
date of the event that requires the adjustment and before completion of the Appraisal Procedure and the determination of the adjustment,
the shares of capital stock issuable upon such exercise by reason of the adjustment required by such event and issuing to such
Holder only the shares of capital stock issuable upon such exercise before giving effect to such adjustment and (ii) paying to
such Holder any amount in cash in lieu of a fractional share of capital stock pursuant to Section 2.3 above; provided,
however, that the Company shall deliver to such Holder an appropriate instrument or due bills evidencing such Holder’s
right to receive such additional shares or such cash.

4.9                
Adjustment of Number of Shares Purchasable. Upon any adjustment of the Exercise Price as provided in Section 4.1,
4.2, 4.4, 4.5 and 4.6, the Holders of the Warrants shall thereafter be entitled to purchase upon the exercise thereof, at the
Exercise Price resulting from such adjustment, the number of shares of Warrant Stock (calculated to the nearest 1/100th of a share)
obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares of Warrant Stock
issuable on the exercise hereof immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting
from such adjustment.

4.10            
Increase of Number of Shares Purchasable. After giving effect to all other provisions in this Article 4 other than
this Section 4.10, the number of shares of Warrant Stock purchasable upon exercise of this Warrant shall be increased when the
Exercise Price is adjusted to an amount below the then-existing par value of the Warrant Stock, including successive adjustments
to the Exercise Price to an amount further below the then-existing par value. The number of additional shares purchasable upon
exercise of this Warrant shall be equal to the number obtained by dividing:

(i)                
The product of (A) the number of shares purchasable upon exercise of the Warrant before application of this Section 4.10
and (B) the difference between the then-existing par value per share of Warrant Stock minus the adjusted Exercise Price, by

(ii)              
The difference between the Fair Market Value of the Common Stock on the Exercise Date minus the then-existing par value
per share of Warrant Stock.

Concurrently with the foregoing
adjustment to the number of additional shares purchasable upon exercise of this Warrant, the Exercise Price shall be adjusted
to be the then-existing par value of the Warrant Stock.

4.11            
Form of Warrants. Irrespective of any adjustments of the number of shares of Warrant Stock purchasable or of the
Exercise Price, the Warrant theretofore or thereafter issued may continue to express the same price and number and kind of shares
as are stated in the Warrant issued on the Original Issue Date.

    13 

     

    

4.12            
Changes in Securities. Notwithstanding any provision in this Article 4 to the contrary and without limitation to
any other provision contained in this Article 4, in the event any securities of the Company are amended, modified or otherwise
altered by operation of this Article 4’s terms or otherwise in any manner whatsoever (including through the anti-dilution
provisions thereof) that results in (i) the reduction of the effective exercise, conversion or exchange price of such securities
payable upon the exercise for, or conversion or exchange into, Common Stock or other securities exercisable for, or convertible
or exchangeable into, Common Stock and/or (ii) such securities becoming exercisable for, or convertible or exchange into (A) more
shares or dollar amount of such securities which are, in turn exercisable for, or convertible or exchangeable into, Common Stock,
or (B) more shares of Common Stock, then such amendment, modification or other alteration shall be treated for purposes of Article
4 as if the securities which have been amended, modified or altered have been terminated and new securities have been issued with
the amended or modified terms. The Company shall make all necessary adjustments (including successive adjustments if required)
to the Exercise Price in accordance with this Article 4, but in no event shall the Exercise Price be greater than it was immediately
prior to the application of this Section 4.12 to the amendment, modification or alteration in question.

4.13            
Maximum Exercise Price. Except as provided in Section 4.5 above, at no time shall the Exercise Price per share of
Warrant Stock exceed the amount set forth in the preamble of this Warrant.

4.14            
Exceptions. Notwithstanding anything to the contrary, Article 4 hereof shall not apply to (i) (A) the issuance and
exercise of options to purchase shares of Common Stock and (B) the issuance of shares of Common Stock, in each case of the foregoing
clause (A) and (B), as made to eligible recipients pursuant to any equity incentive plan duly adopted by the board of directors
of the Company in the ordinary course of business, or (ii) any issuance of shares of Common Stock upon conversion of the Company’s
convertible debt securities outstanding as of the Business Day immediately preceding the Original Issue Date.

4.15            
Notice of Adjustment of Exercise Price. Whenever the number of shares of Common Stock for which this Warrant is
exercisable or the Exercise Price is adjusted as provided under Article 4 hereof:

(i)                
the Company shall compute the adjusted Exercise Price in accordance with this Article 4 and shall prepare a certificate
signed by the treasurer or chief financial officer of the Company setting forth the adjusted Exercise Price and showing in reasonable
detail the facts upon which such adjustment is based, and such certificate shall forthwith be filed at the Designated Office;
and

(ii)              
a notice stating that the Exercise Price has been adjusted and setting forth the adjusted Exercise Price shall forthwith
be prepared by the Company, and as soon as practicable after it is prepared, such notice shall be mailed by the Company at its
expense to the Holder at its last address as it shall appear in the warrant register. If the Board of Directors of the Company
makes any determination of Fair Market Value for purposes of determining such proposed adjustment, then, within thirty (30) days
of the Holder’s receipt of such notice, the Holder shall have the right to use the Appraisal Procedure to determine Fair
Market Value with respect to the entire proposed adjustment.

    14 

     

    

4.16            
Independent Application. Except as otherwise provided herein, all sections of this Article 4 are intended to operate
independently of one another (but without duplication). If an event occurs that requires the application of more than one section
of this Article 4, all applicable sections shall be given independent effect without duplication.

		5.	BENEFICIAL
                                         OWNERSHIP LIMITS; ISSUANCE CAP

5.1                
Beneficial Ownership Limitation.

(a)               
Notwithstanding anything to the contrary contained herein, the Holder shall not receive shares of Warrant Stock upon exercise
of the Warrant to the extent (but only to the extent) that such exercise or receipt would cause the Holder Group to become, directly
or indirectly, a beneficial owner of a number of shares of Common Stock that exceeds the Maximum Percentage of Common Stock Outstanding
as of the Exercise Date (the “Beneficial Ownership Limitation”). The
Beneficial Ownership Limitation (i) may be increased or decreased, in the Holder’s sole discretion, upon 61 days’
written notice to the Company by the Holder, provided, however, that in no event shall the Holder increase such
Beneficial Ownership Limitation to raise the Maximum Percentage in excess of 19.99% as of any date of shares of Common Stock Outstanding
from the date hereof through the Expiration Date and (ii) shall automatically be increased to a Maximum Percentage of 19.99% on
the date that is 15 days prior to the Expiration Date.

(b)              
At the time of delivery of any Exercise Notice, the Holder shall notify the Company if, and only if, a Holder Group would
beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation upon giving effect to such
Exercise Notice. For the avoidance of doubt, upon any failure by the Holder to deliver such notice, any subsequent purported delivery
in such instance of Warrant Stock shall be void and have no effect pursuant to Section 5.1(c) hereof.

(c)               
Any purported delivery of Warrant Stock pursuant to Section 2.1(b) hereof, and any purported payment by the Holder of the
Warrant Price pursuant to Section 2.1(a) and 2.1(c) hereof, in connection with the exercise of the Warrant shall be void and have
no effect to the extent (but only to the extent) that such delivery would violate the Beneficial Ownership Limitation. If any
delivery of Warrant Stock owed to the Holder following exercise of the Warrant is not made, in whole or in part, as a result of
the Beneficial Ownership Limitation, the Company’s obligation to make such delivery shall not be extinguished and the Company
shall deliver such Warrant Stock as promptly as practicable after the Holder gives written notice to the Company that such delivery
would not violate the Beneficial Ownership Limitation (the “Delivery Notice”), provided, however,
that (i) the Holder shall be deemed to have exercised this Warrant in respect of any such delayed Warrant Stock (other than at
the Expiration Date) as of the date of the applicable Delivery Notice and (ii) for the avoidance of doubt, Article 4 hereof and
Article 10 hereof shall remain in full force and effect for such period of delay, and provided, further, however,
that at the Expiration Date and in accordance with the deemed Exercise Notice under Section 2.1(a) hereof, if, without giving
effect to the Beneficial Ownership Limitation, the Warrant would be exercisable for any Warrant Stock, (i) the Holder shall be
entitled to receive from the Company any such remaining Warrant Stock under the terms of this Warrant until such time as the Beneficial
Ownership Limitation would not prohibit such delivery (such Warrant Stock at the Expiration Date, the “Expiration Warrant
Stock”), (ii) the Holder shall be deemed to have exercised this Warrant in respect of all such Expiration Warrant Stock
as of the date of such Holder’s receipt from the Company of the Expiration Warrant Stock (which exercise shall be subject
to Article 4 hereof but not be subject to Sections 4.1 through 4.3 hereof) and (iii) for the avoidance of doubt, Article 10 hereof
shall remain in full force and effect for the period until the delivery of the Expiration Warrant Stock.

    15 

     

    

(d)              
For purposes of this Section 5.1, (i) the term “Maximum Percentage”
shall mean 4.99%; provided, however, that if at any time after the date hereof the Holder Group beneficially owns
in excess of 4.99% of the Outstanding Common Stock (excluding any Common Stock that could be acquired by exercise of this Warrant),
then the Maximum Percentage shall automatically increase to 9.99% so long as any Holder Group owns in excess of 4.99% of such
Common Stock (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon the time when no Holder Group beneficially
owns in excess of 4.99% of such Outstanding Common Stock); and (ii) the term “Holder
Group” shall mean any group in respect of Common Stock, where “group” has the meaning established
under Section 13(d) of the Exchange Act and the rules promulgated thereunder, if the Holder or any other Person having beneficial
ownership of Common Stock beneficially owned by the Holder is a member of such group. In determining the number of shares of Common
Stock Outstanding for purposes of this Section 5.1 and the number of shares that the Holder may at any time acquire pursuant to
the Beneficial Ownership Limitation and the other terms of this Section 5.1, the Holder shall give effect to the last sentence
of Rule 13d-3(d)(1)(i) as promulgated under the Exchange Act, and the Holder may rely on the number of outstanding shares of Common
Stock as reflected in (x) the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with
the Commission, as the case may be, (y) a more recent public announcement by the Company or (z) a more recent notice by the Company
or its transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon written or oral
request of the Holder, the Company shall, within two (2) Business Days of such request, confirm orally and in writing to the Holder
the number of shares of Common Stock then Outstanding. For the avoidance of doubt, if at any time after the Initial Exercise Date
and through the Expiration Date, any Holder Group would become the beneficial owner of any shares of Common Stock pursuant to
an Interest Share Issuance to such Holder Group, the effect of the Beneficial Ownership Limitation in respect of Warrant Stock
shall be determined after giving effect to the beneficial ownership of such shares of Common Stock pursuant to an Interest Share
Issuance pursuant to Section 2.4(f) of the Credit Agreement for purposes of effectuating such intended beneficial ownership limitation
under the Credit Agreement. The provisions of this Section 5.1 shall be construed, corrected and implemented in a manner so as
to effectuate the intended Beneficial Ownership Limitation.

5.2                
Issuance Cap. Unless Stockholder Approval has been previously obtained, in the event that any issuance of Warrant
Stock upon the exercise of this Warrant would, together with (i) any other issuance of shares of Common Stock by the Company to
any holder of any Fifth Amendment Warrant and/or (ii) any issuance of shares of Common Stock pursuant to an Interest Share Issuance
that would, in each case, be aggregated with such proposed issuance under this Warrant for determining whether such issuances
collectively would require approval by a vote of Company stockholders under the applicable listing rules of the Nasdaq Global
Market, any successor stock exchange operated by the NASDAQ Stock Market LLC or any successor thereto (such other issuances in
the foregoing clauses (i) and (ii), the “Related Issuances”), exceed
19.99% of the Common Stock Outstanding on May 24, 2016 (the “Aggregation Date”), the Holder shall receive only
a number of shares of Common Stock, rounded down to the nearest whole number, equal to (A) the maximum number of shares of
Common Stock which could be issued to the Holder and any other recipients of any then-proposed Related Issuances in the aggregate
without the Related Issuances exceeding 19.99% of the Common Stock Outstanding on the Aggregation Date (such maximum number calculated
by giving effect to any then-proposed Related Issuances in connection with any Interest Share Issuance last) multiplied by a ratio
equal to (B) (1) the number of shares of Common Stock that would be otherwise received by the Holder under this Warrant divided
by (2) the number of all of the shares of Common Stock that would be otherwise received by the Holder under this Warrant
and the recipients of any then-proposed Related Issuances in the aggregate. To the extent the Holder is entitled to receive from
the Company a number of shares of Warrant Stock reduced by this Section 5.2, the Company shall pay to the Holder, in satisfaction
of the Company’s obligation to deliver such Warrant Stock, a cash amount equivalent to the Fair Market Value, determined
as of the Exercise Date, of the number of shares of Warrant Stock by which such exercise was reduced within three (3) Business
Days of the Exercise Date.

    16 

     

    

		6.	NO IMPAIRMENT; REGULATORY COMPLIANCE
                                         AND COOPERATION

6.1                
No Impairment. The Company shall not by any action, including, without limitation, amending its charter documents
or through any reorganization, reclassification, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other similar voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may
be necessary or appropriate to protect the rights of the Holder against impairment. Without limiting the generality of the foregoing,
the Company shall take all such action as may be necessary or appropriate in order that the Company may validly and legally issue
fully paid and nonassessable shares of Warrant Stock upon the exercise of this Warrant, free and clear of all Liens, and shall
use its best efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof as may be necessary to enable the Company to perform its obligations under this Warrant. The Company shall not take any
action, enter into any transaction or suffer to exist any event, action or state of facts that would cause the Exercise Price
to be adjusted below the then existing par value of Common Stock (unless the Common Stock is changed to capital stock with no
par value); provided, however, that nothing herein will prevent the operation of any other provision of this Warrant,
including the anti-dilution provisions of Article 4 hereof.

6.2                
No Dilution. If any event shall occur as to which the provisions of Article 4 hereof are not strictly applicable
but the failure to make any adjustment would adversely affect the purchase rights represented by the Warrant in accordance with
the essential intent and principles of such Article (including, without limitation, the issuance of securities other than Common
Stock which have the right to participate in distributions to the holders of Common Stock, the granting of “phantom stock”
rights or “stock appreciation rights”), then, in each such case, the Company shall, upon the request of any Holder,
appoint an investment banking firm of recognized national standing, or any other financial expert that does not (or whose directors,
officers, employees, Affiliates or stockholders do not) have a direct or material indirect financial interest in the Company or
any of its Subsidiaries, who has not been, and, at the time it is called upon to give independent financial advice to the Company,
is not (and none of its directors, officers, employees, Affiliates or stockholders are) a promoter, director or officer of the
Company or any of its Subsidiaries, which shall give their opinion upon the adjustment, if any, on a basis consistent with the
essential intent and principles established in Article 4 hereof, necessary to preserve, without dilution, the purchase rights,
represented by this Warrant. Prior to such determination by such investment banking firm, the Company and the requesting Holder(s),
respectively, shall specify the amount, if any, of the adjustment that such party has determined in good faith to be appropriate.
The adjustment determined by the investment banking firm shall be within the range of the adjustments thus proposed by the parties,
and the costs and fees of such investment banking firm shall be allocated proportionately between the Company, on one hand, and
the Holder, on the other, based on the respective differences between the amount of the adjustment as determined by such investment
banking firm and the amounts of such adjustment proposed by the Company and the Holder. Upon receipt of such opinion, the Company
will promptly mail a copy thereof to the holders of the Warrants and shall make the adjustments described therein.

6.3                
Other Agreements. The Company is not a party to or bound in any manner under, and covenants that it will not enter
into at any time after the date hereof, any agreement or contract (whether written or oral) with respect to any of its securities
which prevents the Company from complying in any respect with the rights granted by the Company hereunder.

    17 

     

    

6.4                
Antitrust Notification. If the Holder determines, in its sole judgment upon the advice of counsel, that an exercise
of this Warrant pursuant to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended (the “HSR Act”), the Company shall file, within seven (7) Business Days after receiving
notice from the Holder of the applicability of the HSR Act and a request to so file, with the United States Federal Trade Commission
(the “FTC”) and the United States Department of Justice (the “DOJ”) the notification and
report form and any supplemental information required to be filed by it pursuant to the HSR Act in connection with the exercise
of this Warrant. Any such notification and report form and supplemental information will be in full compliance with the requirements
of the HSR Act. The Company will furnish to the Holder promptly (but in no event more than five (5) business days) such information
and assistance as such holder may reasonably request in connection with the preparation of any filing or submission required to
be filed by the Holder under the HSR Act. The Company shall respond promptly after receiving any inquiries or requests for additional
information from the FTC or the DOJ (and in no event more than three (3) business days after receipt of such inquiry or request).
The Company shall keep such holder apprised periodically and at such holder's request of the status of any communications with,
and any inquiries or requests for additional information from, the FTC or the DOJ. The Company shall bear all filing or other
fees required to be paid by the Company under the HSR Act or any other applicable law in connection with such filings and all
costs and expenses (including, without limitation, reasonable attorneys' fees and expenses) incurred by the Company in connection
with the preparation of such filings and responses to inquiries or requests. The Company shall also bear 50% of all filing or
other fees required to be paid by the Holder (or the “ultimate parent entity” of the Holder, if any) under the HSR
Act or any other applicable law in connection with such filings and 50% of all costs and expenses (including, without limitation,
reasonable attorneys' fees and expenses) incurred by the Holder in connection with the preparation of such filings and responses
to inquiries or requests, and the Holder shall bear the remaining 50% of such fees, costs and expenses. In the event that this
Section 6.4 is applicable to any exercise of this Warrant, the issuance to the Holder of the applicable Warrant Stock Shares,
and the payment by the Holder of the Warrant Price therefor, shall be subject to the expiration or earlier termination of the
waiting period under the HSR Act (with the Exercise Date being deemed to be the date immediately following the date of such expiration
or early termination).

		7.	RESERVATION AND AUTHORIZATION OF COMMON
                                         STOCK

7.1                
Reservation. The Company shall at all times reserve and keep available for issuance upon the exercise of the Warrant
such number of its authorized but unissued shares of Common Stock as will be required for issuance of the Warrant Stock. All shares
of Warrant Stock issuable pursuant to the terms hereof, when issued upon exercise of this Warrant with payment therefor in accordance
with the terms hereof, shall be duly and validly issued and fully paid and nonassessable, not subject to preemptive rights and
shall be free and clear of all Liens. Before taking any action that would result in an adjustment in the number of shares of Warrant
Stock for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions
thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction over such action.
If any shares of Warrant Stock required to be reserved for issuance upon exercise of the Warrant require registration or qualification
with any Governmental Authority under any federal or state law (including the Securities Act and state securities laws) before
such shares may be so issued, the Company will use its commercially reasonable efforts to register and qualify such shares as
soon as practicable and at its expense.

7.2                
Corporate Action. Before taking any action that would cause an adjustment reducing the Exercise Price below the
then-par value (if any) of the shares of Warrant Stock deliverable upon exercise of the Warrant or that would cause the number
of shares of Warrant Stock issuable upon exercise of the Warrant to exceed (when taken together with all other Outstanding shares
of Common Stock) the number of shares of Common Stock that the Company is authorized to issue, the Company will take any corporate
action that, in the opinion of its counsel, is necessary in order that the Company may validly and legally issue the full number
of fully paid and nonassessable shares of Warrant Stock issuable upon exercise of the Warrant at such adjusted exercise price.

    18 

     

    

		8.	NOTICE OF CORPORATE ACTIONS; TAKING
                                         OF RECORD; TRANSFER BOOKS

8.1                
Notices of Corporate Actions.

In case:

(a)               
the Company shall grant to the holders of its Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class; or

(b)              
the Company shall declare to the holders of its Common Stock any dividend or distribution; or

(c)               
of any reclassification of the Common Stock (other than a subdivision or combination of the Outstanding shares of Common
Stock), or of any consolidation, merger or share exchange to which the Company is a party and for which approval of any stockholders
of the Company is required, or of the sale or transfer of all or substantially all of the assets of the Company; or

(d)              
of the voluntary or involuntary dissolution, liquidation or winding up of the Company;

(e)               
the Company or any Subsidiary shall commence a tender offer for all or a portion of the Outstanding shares of Common Stock
(or shall amend any such tender offer to change the maximum number of shares being sought or the amount or type of consideration
being offered therefor); or

(f)               
the Company or any Subsidiary takes any action or any event or circumstance occurs that impacts the rights of a Holder
set forth herein or in the Credit Agreement, as applicable;

then the Company shall cause
to be filed at the Designated Office, and shall cause to be mailed to the Holder at its last addresses as they shall appear in
the warrant register, at least 30 days prior to the applicable record, effective or expiration date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution or granting of rights or
warrants, or, if a record is not to be taken, the date as of which the holders of Common Stock of record who will be entitled
to such dividend, distribution, rights or warrants are to be determined, (y) the date on which such reclassification, consolidation,
merger, share exchange, sale, transfer, dissolution, liquidation or winding up is expected to become effective, and the date as
of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for
securities, cash or other property deliverable upon such reclassification, consolidation, merger, share exchange, sale, transfer,
dissolution, liquidation or winding up, or (z) the date on which such tender offer commenced, the date on which such tender offer
is scheduled to expire unless extended, the consideration offered and the other material terms thereof (or the material terms
of the amendment thereto). Such notice shall also set forth such facts with respect thereto as shall be reasonably necessary to
indicate the effect of such action on the Exercise Price and the number and kind or class of shares or other securities or property
which shall be deliverable or purchasable upon the occurrence of such action or deliverable upon exercise of the Warrants. Neither
the failure to give any such notice nor any defect therein shall affect the legality or validity of any action described in clauses
(a) through (e) of this Section 8.1.

8.2                
Taking of Record. In the case of all dividends or other distributions by the Company to the holders of its Common
Stock with respect to which any provision hereof refers to the taking of a record of such holders, the Company will in each such
case take such a record and will take such record as of the close of business on a Business Day.

8.3                
Closing of Transfer Books. The Company shall not at any time close its stock transfer books or warrant transfer
books so as to result in preventing or delaying the exercise or transfer of any Warrant.

		9.	OFFICE
                                         OF THE COMPANY

9.1                
As long as the Warrant remains outstanding, the Company shall maintain an office or agency, which may be the principal
executive offices of the Company (the “Designated Office”), where
the Warrant may be presented for exercise, registration of transfer, division or combination as provided in this Warrant. Such
Designated Office shall initially be the office of the Company at 550 South Hope Street, Suite 2850, Los Angeles, California 90071.
The Company may from time to time change the Designated Office to another office of the Company or its agent within the United
States by notice given to any registered Holders at least ten (10) Business Days prior to the effective date of such change.

    19 

     

    

		10.	DILUTION
                                         ADJUSTMENT

10.1            
Dilution Adjustment.

(a)               
In the event that any dividends are declared or paid or any other distribution is made on or with respect to the Common
Stock, the Holder as of the record date established by the Board of Directors of the Company for such dividend or distribution
on the Common Stock shall be entitled to receive a fee (the “Dilution Adjustment”)
in an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends
or distribution that such Holder would have received had the Warrant been exercised as of the date immediately prior to the record
date for such dividend or distribution, such Dilution Adjustment to be payable on the same payment date established by the Board
of Directors of the Company for the payment of such dividend or distribution; provided, however, that if the Company
declares and pays a dividend or distribution on the Common Stock consisting in whole or in part of Common Stock, then no such
Dilution Adjustment shall be payable in respect of the Warrant on account of the portion of such dividend or distribution on the
Common Stock payable in Common Stock and in lieu thereof the applicable adjustment in Article 4 hereof shall apply. The record
date for any such Dilution Adjustment shall be the record date for the applicable dividend or distribution on the Common Stock,
and any such Dilution Adjustment shall be payable to the Persons in whose name the Warrant is registered at the close of business
on the applicable record date.

(b)              
No dividend shall be paid or declared on any share of Common Stock (other than dividends payable in Common Stock for which
an adjustment was made pursuant to Article 4 hereof), unless the Dilution Adjustment, payable in the same consideration and manner,
is simultaneously paid or provided for, as the case may be, in respect of this Warrant in an amount determined as set forth in
this Section 10.1. For purposes of this Warrant, the term “dividends” shall include any pro rata distribution by the
Company, out of funds of the Company legally available therefor, of cash, property, securities (including, but not limited to,
rights, warrants or options and/or securities in connection with a spin-off of the Company) or other property or assets to the
holders of the Common Stock, whether or not paid out of capital, surplus or earnings other than liquidation.

(c)               
Prior to declaring any dividend or making any distribution on or with respect to shares of Common Stock, the Company shall
take all prior corporate action necessary to authorize the issuance of any securities payable as the Dilution Adjustment in respect
of the Warrant.

		11.	MISCELLANEOUS

11.1            
No Implied Waivers. No failure or delay by any party in exercising any right, power or privilege hereunder shall
operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or
the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive
of any rights or remedies provided by law.

    20 

     

    

11.2            
Notices. All notices, requests, consents and other communications required or permitted hereunder shall be in writing
and shall be hand delivered or mailed postage prepaid by registered or certified mail or transmitted by facsimile transmission
(with immediate telephonic confirmation thereafter) or transmitted by email:

(a)               
If to the Holder:

MILFAM II L.P.

3300 S. Dixie Highway, Suite 1-365

West Palm Beach, FL 33405

Attention: Eric Fangmann

Facsimile No.: (619) 923-2908

Telephone No.: (561) 287-5399

Email: info@limadvisory.com

with a
copy to (which shall not constitute notice):

O’Melveny & Myers
LLP

400 South Hope Street

Los Angeles, CA 90071

Attention: Steve Warren

Facsimile No.: (213) 430-6407

Telephone No.: (213) 430-7875, or

(b)              
If to the Company:

Cadiz Inc.

550 South Hope Street, Suite 2850

Los Angeles, California 90071

Attention: Chief Financial Officer

Facsimile No.: 213-271-1614

Email: tshaheen@cadizinc.com

with a
copy to (which shall not constitute notice):

Mitchell
Silberberg & Knupp LLP

11377 W. Olympic Blvd.

Los Angeles, CA 90065

Facsimile No.: (310) 312-3100

Attention: Kevin Friedmann, Esq.

Email: kxf@msk.com

or
at such other address as the parties each may specify by written notice to the others, and each such notice, request, consent
and other communication shall for all purposes of the Warrant be treated as being effective or having been given when delivered
if delivered personally, upon receipt of facsimile confirmation if transmitted by facsimile, upon transmission of email if transmitted
by email, or, if sent by mail, at the earlier of its receipt or 72 hours after the same has been deposited in a regularly maintained
receptacle for the deposit of United States mail, addressed and postage prepaid as aforesaid.

    21 

     

    

11.3            
Indemnification. If the Company fails to make, when due, any payments provided for in this Warrant, the Company
shall pay to the Holder (a) interest at the Applicable Rate on any amounts due and owing to such Holder and (b) such further amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees and expenses
incurred by such Holder in collecting any amounts due hereunder. The Company shall indemnify, defend and hold harmless the Holder
and the Holders of any Warrant Stock issued upon the exercise of this Warrant from and against any and all liability, loss, cost,
damage, reasonable attorneys’ and accountants’ fees and expenses, court costs and all other out-of-pocket expenses
incurred in connection with or arising from any default hereunder by the Company or the enforcement of its rights hereunder as
against the Company. This indemnification provision shall be in addition to the rights of such Holder or Holders to bring an action
against the Company for breach of contract based on such default hereunder.

11.4            
Limitation of Liability. No provision hereof, in the absence of affirmative action by the Holder to purchase shares
of Warrant Stock, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of such
Holder to pay the Exercise Price for any Warrant Stock other than pursuant to an exercise of this Warrant or any liability as
a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. The Holder shall
not, by virtue hereof, be entitled to any rights of a stockholder of the Company and nothing contained in this Warrant shall be
construed as conferring upon the Holder the right to vote or to consent or to receive notice as a stockholder in respect of meetings
of stockholders for the election of directors of the Company or any other matters or any rights whatsoever as a stockholder of
the Company.

11.5            
Remedies. The Holder of the Warrant and/or Warrant Stock, in addition to being entitled to exercise its rights granted
by law, including recovery of damages, shall be entitled to specific performance of its rights provided under this Warrant. The
Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the
provisions of this Warrant and hereby agrees, in an action for specific performance, to waive the defense that a remedy at law
would be adequate.

11.6            
Successors and Assigns. This Warrant and the rights evidenced hereby shall inure to the benefit of and be binding
upon the successors of the Company and the permitted successors and assigns of the Holder. The provisions of this Warrant are
intended to be for the benefit of all Holders from time to time of this Warrant and to the extent applicable, all Holders of shares
of Warrant Stock issued upon the exercise hereof (including transferees), and shall be enforceable by any such Holder.

    22 

     

    

11.7            
Amendment. The prior written consent of the Company and the Required Holders shall be required for any change, waiver
or amendment to this Warrant. Any change, waiver or amendment so approved shall be binding upon all existing and future holders
of this Warrant and any other Fifth Amendment Warrants; provided, however, that no such change, waiver or amendment,
as applied to any of the Fifth Amendment Warrants held by any particular holder of Fifth Amendment Warrants, shall, without the
written consent of that particular holder, (i) disproportionately and materially adversely affect any rights under such particular
holder’s Fifth Amendment Warrant (other than as reflected by the different number of shares of Warrant Stock issuable to
such holder); or (ii) modify any of the provisions of, or impair the right of any holder of Fifth Amendment Warrants under, this
Section 11.7. This Warrant cannot be changed, modified, discharged or terminated by oral agreement.

11.8            
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision
or the remaining provisions of this Warrant.

11.9            
Headings. The headings and other captions in this Warrant are for the convenience and reference only and shall not
be used in interpreting, construing or enforcing any provision of this Warrant.

11.10        
Governing Law. IN ALL RESPECTS, INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, THIS WARRANT
SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT
OF LAW PRINCIPLES AND ANY APPLICABLE LAWS OF THE UNITED STATES OF AMERICA.

11.11        
Jurisdiction. Each of the Company and the Holder hereby irrevocably and unconditionally submits for itself and its
property in any legal action or proceeding relating to this Warrant, or for recognition and enforcement of any judgment in respect
thereof, to the exclusive general jurisdiction of the courts of the Supreme Court of the State of New York sitting in New York
County, the courts of the United States for the Southern District of New York, and appellate courts from any thereof, consents
that any such action or proceeding may be brought in such courts and waives any objection that it may now or hereafter have to
the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient
court and agrees not to plead or claim the same, agrees that service of process in any such action or proceeding may be effected
by delivery of notice pursuant to Section 11.2 hereof and agrees that nothing herein shall affect the right to effect service
of process in any other manner permitted by law.

11.12        
Waiver of Jury Trial. EACH OF THE COMPANY AND THE HOLDER WAIVES ANY RIGHT TO TRIAL BY JURY ON ANY CLAIM, DEMAND,
ACTION OR CAUSE OF ACTION (A) ARISING UNDER THIS WARRANT OR (B) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THIS WARRANT
OR THE TRANSACTIONS RELATED HERETO, IN EACH CASE WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE. EACH OF THE COMPANY AND THE
HOLDER AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY,
AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS CLAUSE WITH ANY COURT AS WRITTEN EVIDENCE
OF THE CONSENT OF THE COMPANY AND THE HOLDER TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH OF THE COMPANY AND THE HOLDER
ACKNOWLEDGES THAT IT HAS HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL REGARDING THIS SECTION 11.12, THAT IT FULLY UNDERSTANDS ITS
TERMS, CONTENT AND EFFECT, AND THAT IT VOLUNTARILY AND KNOWINGLY AGREES TO THE TERMS OF THIS SECTION 11.12.

11.13        
Entire Agreement. This Warrant contains the entire agreement with respect to the subject matter hereof and supersedes
and replaces all other prior agreements, written or oral, with respect to the subject matter hereof.

11.14        
Originals. A signed copy of this Warrant delivered by facsimile, e-mail or other means of electronic transmission
shall be deemed to have the same legal effect as delivery of an original copy of this Warrant.

[Execution
Page Follows]

    23 

     

    

IN WITNESS
WHEREOF, the Company has caused this Warrant to be duly executed as of the Original Issue Date.

CADIZ INC.

By: /s/ Timothy J.
Shaheen
 Name:Timothy J. Shaheen
 Title:CFO

    24 

     

    

ANNEX A
TO THE WARRANT

EXERCISE
NOTICE

[To be executed
only upon exercise of Warrant]

The undersigned
registered owner of this Warrant irrevocably exercises this Warrant for the purchase of ______ shares of Common Stock of Cadiz
Inc. and herewith makes payment therefor in __________, all at the price and on the terms and conditions specified in this Warrant
and requests that the shares of Common Stock hereby purchased (and any securities or other property issuable upon such exercise)
be issued in the name of, and delivered to, as applicable, _________________, whose address is __________________________________
____________________________________________________________________, and, if such shares of Common Stock shall not include all
of the shares of Common Stock issuable as provided in this Warrant, that a new Warrant of like tenor and date for the balance
of the shares of Common Stock issuable hereunder be delivered to the undersigned.

TO DELETE
THE FOLLOWING BRACKETED LANGUAGE IF INAPPLICABLE AT EXERCISE DATE:[The undersigned hereby notifies Cadiz Inc. that a Holder
Group would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation set forth in
this Warrant upon giving effect to this Exercise Notice. Pursuant to such limitation, Cadiz Inc. shall give effect to this Exercise
Notice in accordance with such limitation as of [INSERT DATE], the date hereof]. 

_______________________________

(Name of Registered Owner)

_______________________________

(Signature of Registered Owner)

_______________________________

(Street Address)

_______________________________

(City) (State) (Zip Code)

	 	 
	NOTICE:	The signature on this
    Exercise Notice must correspond with the name as written upon the face of the within Warrant in every particular, without
    alteration or enlargement or any change whatsoever.

 

    A-1

     

    

ANNEX B
TO THE WARRANT

ASSIGNMENT
FORM

FOR VALUE
RECEIVED the undersigned registered owner of this Warrant hereby assigns unto the assignee named below all of the rights of the
undersigned under this Warrant, with respect to the number of shares of Common Stock set forth below:

	Name
        and Address of Assignee
	 	No.
        of Shares of Common Stock

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

and does hereby irrevocably
constitute and appoint ________ _____________ attorney-in-fact to register such transfer onto the books of Cadiz Inc. maintained
for the purpose, with full power of substitution in the premises.

	Dated:	Print Name:
	 	 
	Signature:	Witness
	 	 
	 	 
	NOTICE:	The signature on this assignment
    must correspond with the name as written upon the face of the within Warrant in every particular, without alteration or enlargement
    or any change whatsoever.
	 	 	 

 

 

 

B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]